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A B S T R A C T
Background
Cystic fibrosis is a common life-shortening genetic disorder in the Caucasian population (less common in other ethnic groups) caused
by the mutation of a single gene that codes for the production of the cystic fibrosis transmembrane conductance regulator protein. This
protein coordinates the transport of salt (and bicarbonate) across cell surfaces and the mutation most notably affects the airways. In
the lungs of people with cystic fibrosis, defective protein results in a dehydrated surface liquid and compromised mucociliary clearance.
The resulting thick mucus makes the airway prone to chronic infection and inflammation, which consequently damages the structure
of the airways, eventually leading to respiratory failure. Additionally, abnormalities in the cystic fibrosis transmembrane conductance
regulator protein lead to other systemic complications including malnutrition, diabetes and subfertility.
Five classes of mutation have been described, depending on the impact of the mutation on the processing of the cystic fibrosis
transmembrane conductance regulator protein in the cell. In class I mutations, the presence of premature termination codons prevents
the production of any functional protein resulting in a severe cystic fibrosis phenotype. Advances in the understanding of the molecular
genetics of cystic fibrosis has led to the development of novelmutation-specific therapies. Therapies targeting class Imutations (premature
termination codons) aim to mask the abnormal gene sequence and enable the normal cellular mechanism to read through the mutation,
potentially restoring the production of the cystic fibrosis transmembrane conductance regulator protein. This could in turn make salt
transport in the cells function more normally and may decrease the chronic infection and inflammation that characterises lung disease
in people with cystic fibrosis.
Objectives
To evaluate the benefits and harms of ataluren and similar compounds on clinically important outcomes in people with cystic fibrosis
with class I mutations (premature termination codons).
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Search methods
We searched the Cochrane Cystic Fibrosis Trials Register which is compiled from electronic database searches and handsearching of
journals and conference abstract books. We also searched the reference lists of relevant articles. Last search of Group’s register: 24
October 2016.
We searched clinical trial registries maintained by the EuropeanMedicines Agency, the USNational Institutes of Health and theWHO.
Last search of clinical trials registries: 28 November 2016.
Selection criteria
Randomised controlled trials of parallel design comparing ataluren and similar compounds (specific therapies for class I mutations)
with placebo in people with cystic fibrosis who have at least one class I mutation. Cross-over trials were reviewed individually to evaluate
whether data from the first treatment arm could be included. We excluded trials that combined therapies for premature termination
codon class I mutations with other mutation-specific therapies.
Data collection and analysis
The authors independently assessed the risk of bias and extracted data from the included trial; they contacted trial authors for additional
data.
Main results
Our searches identified 28 references to eight trials; five trials were excluded (three were cross-over and one was not randomised and
one did not have relevant outcomes), one cross-over trial is awaiting classification pending provision of data and one trial is ongoing.
The included parallel randomised controlled trial compared ataluren to placebo for a duration of 48 weeks in 238 participants (age
range 6 to 53 years) with cystic fibrosis who had at least one nonsense mutation (a type of class I mutation).
The quality of evidence and risk of bias assessments for the trial were moderate overall. Random sequence generation, allocation
concealment and blinding of trial personnel were well-documented; participant blinding was less clear. Some participant data were
excluded from the analysis. The trial was assessed as high risk of bias for selective outcome reporting, especially when reporting on the
trial’s post hoc subgroup of participants by chronic inhaled antibiotic use.
The trial was sponsored by PTC Therapeutics Incorporated with grant support by the Cystic Fibrosis Foundation, the Food and Drug
Administration’s Office of Orphan Products Development and the National Institutes of Health (NIH).
The trial reported no significant difference between treatment groups in quality of life, assessed by the Cystic Fibrosis Questionnaire-
Revised respiratory domain score and no improvement in respiratory function measures (mean difference of relative change in forced
expiratory volume at one second 2.97% (95% confidence interval -0.58 to 6.52)). Ataluren was associated with a significantly higher
rate of episodes of renal impairment, risk ratio 17.70 (99% confidence interval 1.28 to 244.40). The trial reported no significant
treatment effect for ataluren for the review’s secondary outcomes: pulmonary exacerbation; computerised tomography score; weight;
body mass index; and sweat chloride. No deaths were reported in the trial.
A post hoc subgroup analysis of participants not receiving chronic inhaled tobramycin (n = 146) demonstrated favourable results
for ataluren (n = 72) for relative change in % predicted forced expiratory volume at one second and pulmonary exacerbation rate.
Participants receiving chronic inhaled tobramycin appeared to have a reduced rate of pulmonary exacerbation compared to those not
receiving chronic inhaled tobramycin. This drug interaction was not anticipated and may affect the interpretation of the trial results.
Authors’ conclusions
There is currently insufficient evidence to determine the effect of ataluren as a therapy for people with cystic fibrosis with class I
mutations. Future trials should carefully assess for adverse events, notably renal impairment and consider the possibility of drug
interactions. Cross-over trials should be avoided given the potential for the treatment to change the natural history of cystic fibrosis.
P L A I N L A N G U A G E S U M M A R Y
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What are the effects of ataluren and similar compounds (specific therapies for premature termination codon (class I) mutations) on
clinical outcomes (quality of life, lung function and adverse effects) in people with cystic fibrosis?
Background
In people with cystic fibrosis, the gene encoding a protein called the cystic fibrosis transmembrane conductance regulator is faulty. In
particular, this affects the airways, which become dehydrated making it difficult to clear thick mucus, which in turn leads to progressive
lung infection and damage and a reduction in life expectancy. Ataluren and similar compounds can mask the abnormal gene sequence
and may be able to restore production of the faulty protein in people with certain cystic fibrosis mutations (premature termination
codon (class I) mutations). These treatments aim to help the airways retain more water allowing them to clear the mucus better, so that
these people develop fewer lung infections.
Search date
The evidence is up to date as of 24 October 2016.
Study characteristics
We found one trial (238 people took part) comparing ataluren to placebo (a dummy treatment with no active medication). The trial
lasted 48 weeks and included both males and females aged six years and older. Everyone taking part had at least one copy of a nonsense
mutation (a type of class I mutation that causes cystic fibrosis).
Key Results
In those people who took ataluren, there was no improvement in clinical outcomes such as quality of life, lung function, exacerbations
(flare up of disease), sweat chloride (salt) levels or weight. The trial found that kidney damage was more common in people who
took ataluren. The trial investigators then analysed the results in a way that they hadn’t planned originally and looked at how ataluren
or placebo affected people depending on whether they were using inhaled tobramycin on a long-term basis or not. They found that
amongst those not taking inhaled tobramycin, lung function declined at a slower rate and there were fewer exacerbations in the ataluren
group compared to the placebo group.
We have not found enough high-quality evidence currently to determine the effect of ataluren for treating people with cystic fibrosis.
We recommend that future trials are designed and reported clearly so that their results can be included in a systematic review.
Quality of the evidence
We judged the quality of the evidence was moderate with uncertainty due to how widely the results varied between participants. We
are satisfied that everyone taking part had an equal chance of being in either group (ataluren or placebo) and that no one could work
out which group the next person would be put into, so that healthier people did not receive the treatment and make the results seem
better. We believe that the clinicians running the trial and those taking part in the trial did not know which treatment each person was
receiving. We have some concerns on the emphasis the investigators have placed on the results of a comparison they had not planned
(use of long-term inhaled tobramycin). Unfortunately, the trial did not report all their results clearly; sometimes they did not report
them in a way that we could use in the review and sometimes they did not report the data at all. This affected the certainty with which
we judged the overall results.
Trial Funding Sources
The trial was sponsored by PTC Therapeutics Incorporated. The Cystic Fibrosis Foundation, the Food and Drug Administration’s
Office of Orphan Products Development and the National Institutes of Health (NIH) also supported the trial.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ataluren compared with placebo for people with CF with class I mutations (PTCs): long- term outcomes
Patients or population: adults and children with CF with at least one class I mutation (PTC)
Settings: outpatient
Intervention: oral ataluren
Comparison: oral placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Ataluren
Health Related Quality
of Life
Scale: age appropriate
versions of CFQ-R ques-
t ionnaire
Follow up: 48 weeks
No signif icant dif f erences were found between treatment groups for the
CFQ-R
232
(1 study)1
⊕⊕⊕©
moderate2
Data provided by inves-
t igators were analysed
via a MMRM analysis
Respiratory function:
%predicted FEV (rela-
tive change from base-
line)
Follow up: 48 weeks
The mean (SD) relat ive
change f rom baseline in
the placebo group was
-5.5% (12.56%)
The mean (SD) relat ive
change f rom baseline in
the the ataluren group
was -2.53% (13.25%)
MD 2.97%(95% CI -0.58
to 6.52%).
232
(1 study)
⊕⊕⊕⊕
high
Data provided by inves-
t igators were analysed
via a MMRM analysis
Adverse events relat-
ing to treatment
Scale: m ild, moderate,
severe
Episodes of oropharyn-
geal pain
14/ 118 placebo part ic-
ipants experienced this
adverse event.
4/ 120 ataluren part ici-
pants experienced this
adverse event.
RR 0.28 (95% CI 0.10 to
0.83) (P = 0.02).
238
(1 study)
⊕⊕⊕©
moderate3
Adverse events were
graded by severity (1
- 4); however, de-
tails of criteria for
grade 1-3 classif ica-
t ions were not re-
ported. Adverse events
occurring in more than
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10%of part icipants was
reported. There was
no signif icant dif f er-
ence between treat-
ment groups for all
other recorded adverse
events
Adverse events relat ing
to treatment
Scale: m ild, moderate,
severe
Episodes of ‘‘acute kid-
ney injury’’
1/ 118 placebo part ici-
pants experienced this
adverse event.
18/ 120 ataluren part ic-
ipants experienced this
adverse event.
RR 17.70 (95% CI 2.40
to 130.47) (P = 0.005).
238
(1 study)
⊕⊕⊕©
moderate3
Adverse events were
graded by severity (1
- 4); however, de-
tails of criteria for
grade 1-3 classif ica-
t ions were not re-
ported. Adverse events
occurring in more than
10%of part icipants was
reported. There was
no signif icant dif f er-
ence between treat-
ment groups for all
other recorded adverse
events
Pulmonary exacerba-
tions - protocol-de-
fined (modified Fuchs’
criteria) Scale: rate Fol-
low up: 48 weeks
The mean (SD) proto-
col-def ined pulmonary
exacerbat ion rate in the
placebo group was 1.78
(2.15)
The mean (SD) proto-
col-def ined pulmonary
exacerbat ion rate in the
ataluren groups was 1.
42 (2)
MD -0.36 (95% CI -0.89
to 0.17).
232
(1 study)
⊕⊕⊕©
moderate2
Data provided by inves-
t igators were analysed
via a MMRM analysis
Nutrition and growth
Change in:
a) weight (kg)
b) BMI (kg/ m2)
c) height (m)
Follow up: 48 weeks
No signif icant dif f erences between treatment groups were found for the
change in body weight and BMI
232
(1 study)1
⊕⊕⊕©
moderate2
Data provided by inves-
t igators were analysed
via a MMRM analysis
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Sweat chloride level -
change from baseline
Scale: mmol/ L
Follow up: 48 weeks
The mean (SD) change
f rom baseline in the
placebo group was -0.6
(10.27)
The mean (SD) change
f rom baseline in the
ataluren group was -1.3
(8.94)
MD -0.70 mmol/ L (95%
CI -3.37 to 1.97).
194
(1 study)
⊕⊕⊕©
moderate2
Data provided by inves-
t igators were analysed
via a MMRM analysis
M ortality rate The trial reported zero deaths in both treatment groups. 232
(1 study)
⊕⊕⊕©
moderate4
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CF: cyst ic f ibrosis; CFQ-R: cyst ic f ibrosis quest ionnaire - revised; CI: conf idence interval; FEV : f orced expiratory volume at one second; ITT : intent ion to treat; M D: mean
dif ference; M M RM : mixed model repeated measures analysis - based on the average ef fect across all post-baseline visits; PTC: premature term inat ion codon; RR: risk rat io;
SD: standard deviat ion.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1. Stated that 238 part icipants were randomised, 232 in ITT populat ion and 203 completed the study. Unclear how many
part icipants were evaluated for the outcome.
2. Evidence downgraded due to imprecision; study not powered to assess signif icant change in the outcome.
3. The power of the study to reliably report adverse events (acute kidney injury) was low, ref lected in the wide CI for RR.
4. Evidence downgraded due to imprecision; no deaths were reported in the trial, therefore a relat ive comparison between
groups cannot be made.
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B A C K G R O U N D
A glossary of terms specific to this review can be found in the
appendices (Appendix 1); a more general glossary of terms used
in Cochrane systematic reviews can be accessed at Cochrane
Glossary.
Description of the condition
Cystic fibrosis (CF) is a common life-shortening genetic disorder
in theCaucasianpopulation (less common in other ethnic groups).
In the UK around 1 in 3000 newborn infants are affected and in
2013 median predicted survival was reported as just over 36 years
of age (UK CF Trust 2014; Welsh 2001). The condition is caused
by themutation of a single gene, which codes for the production of
the cystic fibrosis transmembrane conductance regulator (CFTR)
protein (Welsh 2001). After transcription (being produced in the
centre of the cell), the protein is transported to the cell membrane,
where it has an important role as a chloride channel, co-ordinating
the transport of salt across cell surfaces (Boucher 2007).
Lung disease is the major cause of morbidity and mortality in CF
(Davis 2006). In the airways, the CFTR protein does not function
correctly resulting in increased fluid and sodium resorption away
from the airway surface; in turn this leads to a dehydrated airway
surface liquid and compromised clearance of these secretions (
Boucher 2007). The resulting thick mucus in the airway provides
a site for infection. Chronic airway infection and inflammation
causes damage to the structure of the airways, which eventually
results in respiratory failure.
Approximately 2000 mutations of the CFTR gene have been de-
scribed. Five classes of mutation have been characterised, depend-
ing on the impact of the mutation on the processing of the CFTR
protein in the cell (CFMD 2011) (Table 1).
This review is focused on class I mutations which stop the normal
protein-producing mechanisms of the cell; as a result of this no
significant amounts of CFTR protein are produced. The muta-
tions change the sequence of the gene and a piece of DNA is in-
serted that tells the cell to stop producing the protein. The normal
process of producing a protein in the cell is called transcription
and this is faulty in class I mutations. There are different ways class
I mutations cause this effect; they can insert a sequence of DNA
that makes no sense (a nonsense mutation) or they can produce
a sequence that directs the normal cellular mechanism to stop (a
stop codon mutation). Collectively, these different types of mu-
tation are known as premature termination codons (PTCs), but
essentially have the same outcome of no functional protein being
produced (Friedman 2014; McElroy 2013; Nicholson 2010).
Class I mutations are seen in approximately 10% of people with
CF (with higher proportions seen in the Ashkenazi Jewish popu-
lation) and they result in a severe CF phenotype with no signifi-
cant functional protein being synthesised (Kerem 1997; McKone
2006).
Description of the intervention
Advances in the understanding of the molecular genetics of CF
have led to the development of novel mutation-specific therapies.
One potential strategy has been to correct class Imutations (PTCs)
by using drugs that mask the abnormal gene sequence of the mu-
tation and enable the normal cellular mechanism to read through
the mutation and produce a full length of protein. The CFTR
protein would then be transported normally to the cell membrane,
where it might correct the CF salt transport defect.
Previous studies have demonstrated that aminoglycoside antibi-
otics (e.g. gentamicin) have the ability to read through class I mu-
tations (PTCs) resulting in expression of full length CFTR protein
and significant changes of the salt transporting defect towards nor-
mal (Clancy 2001; Howard 1996; Wilschanski 2003). Although
gentamicin is widely used as an antibiotic for people with CF, it is
not an ideal agent for long-term delivery because of concerns over
renal and ototoxicity (Wilschanski 2003).
High-throughput screening has identified a molecule called
ataluren (formerly PTC124), which has potential as an oral class
I (PTC) therapy (McElroy 2013; Welch 2007). In the laboratory,
ataluren has been shown to have the ability to enable read through
of class I (PTC) mutations (Welch 2007).
How the intervention might work
By correcting the underlying molecular genetic defect, ataluren
and related compounds may reverse the abnormal salt transport
that characterises CF. This may restore the ability of the airway to
prevent airway infection and inflammation and improve respira-
tory function. In addition, as a systemic treatment, ataluren may
have impact on other parts of the body that are affected by the CF
salt transport defect.
Why it is important to do this review
A number of different mutation-specific therapies are under in-
vestigation. These include potentiators, which improve the com-
promised function of CFTR that has reached the cell membrane
(class III and IV mutations) and also correctors, which increase
the amount of CFTR in the cell membrane (class II mutations)
(Table 1). A Cochrane review has recently been published for trials
assessing potentiators (Patel 2015) and a review is currently being
undertaken for corrector therapies (Sinha 2014). At present, there
are no known trials for therapies specific to class V mutations.
It is important that the randomised controlled trials (RCTs) assess-
ing ataluren or similar compounds are critically appraised. This
will allow the analysis of the data outlining the benefits and harms
of these therapies in people with CF. It is important that funding
bodies have a clear evidence-base on which to assess novel mu-
tation-specific CF therapies. It is likely that these therapies will
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represent a significant healthcare resource. In addition, a critical
appraisal of included trials will help inform future trial design.
O B J E C T I V E S
To evaluate the benefits and harms of ataluren and similar com-
pounds on clinically important outcomes in people with CF with
class I mutations (PTCs).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of parallel de-
sign (published or unpublished). We excluded quasi-RCTs due
to a greater risk of selection bias. Cross-over trials were reviewed
individually to evaluate if data from the first treatment arm may
be included; however, since these therapies aim to correct the un-
derlying gene defect, there is significant potential for longer-term
impact on outcomes and this is not an ideal trial design.
Types of participants
We included trials involving children or adults with CF, of any
severity, as confirmed either by the presence of two disease-caus-
ing mutations, or by a combination of a positive sweat test and
recognised clinical features of CF.We only included trials in which
participants had at least one PTC (nonsense or stop codon) mu-
tation.
Types of interventions
We included trials in which ataluren (or similar compounds for
PTC class I mutations) was compared with either placebo or an-
other intervention. We excluded trials that combined therapies
for PTC class I mutations with other mutation-specific therapies.
No trials comparing different dosing regimens of these therapies
were eligible for inclusion based on the aforementioned criteria. In
future updates, we will include trials comparing different dosing
regimens of therapies for PTC class I mutations if we identify such
trials.
Types of outcome measures
Primary outcomes
1. Quality of life (QoL) (measured using validated
quantitative scales or scores (e.g. Cystic Fibrosis Questionnaire-
Revised (CFQ-R) (Quittner 2009))
i) total QoL score
ii) different sub-domains
2. Respiratory function measures (litres or per cent (%)
predicted for age, sex and height)
i) forced expiratory flow rate at one second (FEV )
(relative change from baseline)
ii) FEV (absolute values)
iii) forced vital capacity (FVC) (absolute values and
relative change from baseline)
3. Adverse events
i) graded by review authors as mild (therapy does not
need to be discontinued)
ii) graded by review authors as moderate (therapy is
discontinued, and the adverse effect ceases)
iii) graded by review authors as severe (life-threatening or
debilitating, or which persists even after treatment is
discontinued)
Secondary outcomes
1. Survival
i) time to event (death or lung transplant)
ii) mortality rate
2. Hospitalisation
i) number of days
ii) number of episodes
iii) time to next hospitalisation
3. School or work attendance (i.e. number of days missed)
4. Extra courses of antibiotics (measured as time-to the next
course of antibiotics and the total number of courses of
antibiotics)
i) oral
ii) intravenous
iii) inhaled
5. Pulmonary exacerbations (either physician- or protocol-
defined)
6. Radiological measures of lung disease (assessed using any
scoring system)
i) chest radiograph score
ii) computerised tomogram (CT) score
7. Acquisition of respiratory pathogens
i) Pseudomonas aeruginosa (P aeruginosa)
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ii) Staphylococcus aureus (S aureus)
iii) Haemophilus influenzae (H influenzae)
iv) other significant pathogens
8. Eradication of respiratory pathogens (as defined by trial
authors)
i) P aeruginosa
ii) S aureus
iii) H influenzae
iv) other significant pathogen
9. Nutrition and growth (measured as relative change from
baseline) (including z scores or centiles)
i) weight
ii) body mass index (BMI)
iii) height
10. Sweat chloride (change from baseline) as a measure of
CFTR function in sweat glands
11. Cost effectiveness (cost utility assessed as comparison of
impact on quality of adjusted life years)
Search methods for identification of studies
Electronic searches
We identified relevant studies from the Cochrane Cystic Fibrosis
andGeneticDisordersGroup’s Cystic Fibrosis Trials Register using
the term: ’drugs that correct stop codon mutations’.
This register has been compiled from electronic searches of the
Cochrane Central Register of Controlled Trials (CENTRAL) (up-
dated each new issue of the Cochrane Library), weekly searches of
MEDLINE, a search of Embase to 1995 and the prospective hand-
searching of two journals - Pediatric Pulmonology and the Journal
of Cystic Fibrosis. Unpublished work is identified by searching the
abstract books of three major cystic fibrosis conferences: the Inter-
national Cystic Fibrosis Conference; the European Cystic Fibrosis
Conference and the North American Cystic Fibrosis Conference.
For full details of all searching activities for the register, please see
the relevant sections of the Cochrane Cystic Fibrosis and Genetic
Disorders Group Module.
Date of the most recent search: 24 October 2016.
We also searched clinical trial registries maintained by the Eu-
ropean Medicines Agency (www.clinicaltrialsregister.eu), the US
National Institutes of Health (clinicaltrials.gov) and the WHO (
www.who.int/ictrp/en/).
Date of the most recent search: 28 November 2016.
Searching other resources
We screened references of included trials to identify other poten-
tially relevant trials. We also contacted authors of included trials,
leaders in the field, and companies known to be developing and
investigating therapies for PTC class I mutations, to identify any
trials which may have been missed by these searches.
Data collection and analysis
Selection of studies
Two authors (AA and CH) independently assessed the suitability
of each trial identified by the outlined search. If any disagreement
had arisen on the suitability of a trial for inclusion in the review, we
would have attempted to reach a consensus by discussion, failing
which a third author (KWS) would have arbitrated.
Data extraction and management
Two authors (AA and CH) independently extracted relevant data
from the only included trial using a standardised data extraction
form. If any disagreement had arisen on data extraction, we would
have attempted to reach a consensus by discussion, failing which
a third author (KWS) would have arbitrated.
We intended to extract QoL scores ideally as relative change from
baseline ((measurement at end of treatment - measurement at
baseline) / measurement at baseline) x 100); however, data were
not reported for this analysis and instead we extracted the abso-
lute change from baseline. We extracted data for FEV (relative
change from baseline). The mean and standard error for the mean
for relative change from baseline in FEV and FVCwere reported
at 8, 16, 24, 32, 40 and 48 weeks through graphical represen-
tation and two reviewers (AA and CH) independently estimated
these data. Regarding adverse events, we extracted data for severe
adverse events (i.e. participants who required discontinuation of
therapy). The trial report presented data for adverse events occur-
ring in more than 10% of participants; however, the report did
not provide information regarding whether treatment required in-
terruption or not. Furthermore, the report presented data as the
number of each adverse event occurring (where a participant may
have had more than one adverse event), which prevented extrac-
tion of the number of participants who experienced an adverse
event.
With regards to the secondary outcome, pulmonary exacerba-
tion, we extracted the rate of pulmonary exacerbation and noted
both protocol-defined and physician-defined rates. For the out-
come, nutrition, the trial investigators reported insufficient data
for change from baseline in each treatment arm and instead we ex-
tracted the difference in change in body weight and BMI between
ataluren and placebo. For total lung CT score and sweat chloride
concentration, we extracted the absolute change from baseline.
In future updates, if trials are included with different dosing regi-
mens, we will combine results of all dosing regimens together in a
single analysis and subsequently undertake a subgroup analysis to
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assess the doses individually. We planned to report data as imme-
diate (up to and including one month), medium term (over one
month and up to six months) and long term (over six months).
We extracted data for up to 48 weeks and estimates at 8, 16, 24,
32 and 40 weeks (when presented) for selected outcomes. As only
one trial met the inclusion criteria for the review, we were unable
to combine results of multiple trials. We plan to do this in future
when more trials are available for inclusion.
Assessment of risk of bias in included studies
Two authors (AA and CH) independently assessed the risk of bias
for the included trial using the Cochrane risk of bias tool (Higgins
2011a). This included assessment of the followingmethodological
aspects of the trial:
1. procedure for randomisation (selection bias);
2. allocation concealment (selection bias);
3. masking (blinding) of the intervention from participants,
clinicians, and trial personnel evaluating outcomes (performance
bias);
4. missing outcome data (attrition bias);
5. selective outcome reporting (reporting bias);
6. other sources of bias (e.g. the influence of funding sources
or industry on trial characteristics and presented results).
We assessed whether all participants were included in an inten-
tion-to-treat analysis, regardless of whether they completed the
treatment schedule or not. If disagreement had arisen on the as-
sessment of risk of bias, we would have attempted to reach a con-
sensus by discussion, failing which a third author (KWS) would
have arbitrated.
Measures of treatment effect
For binary outcomes, we calculated the treatment effect for each
outcome using the risk ratio (RR) and 95% confidence intervals
(CIs); but (in a post hoc change) for the analysis of individual
adverse events we have used 99% CIs as the type I error rate (e.g.
false positive) is greatly inflated with a large number of tests. For
continuous outcomes, we calculated the mean change from base-
line and standard deviation (SD) for each group. We converted
any reported standard errors to SDs. We calculated the mean dif-
ference (MD) and 95% CIs. For the eight-weekly estimates of the
relative change from baseline in FEV (as well as the subgroup
analysis by chronic inhaled tobramycin use for this outcome) and
FVC, the trial report did not state the number of participants for
each time point. For these estimated data, as the withdrawal rate
was 14% in the ataluren group and 11% in the placebo group, we
felt it appropriate to use the respective ITT population for each
treatment group and subgroup. For QoL, CFQ-R was the ques-
tionnaire used and we intended to calculate theMD and 95%CIs;
however, insufficient data were reported in the trial. Inclusion of
a single trial prevented analysing pooled estimates.
In the included trial, investigators analysed continuous outcomes
over 48 weeks via a mixed model repeated measures analysis
(MMRM) based on the average effect across all post-baseline vis-
its (Kerem 2014). Such an analysis is longitudinal and uses all
available data at every visit. We have presented week-48 data for
relative change in FEV , pulmonary exacerbation rate, total lung
CT scores and change in sweat chloride concentration from the
MMRM model for the effect at 48 weeks derived from the treat-
ment by visit term in the model (so data presented as ’up to 48
weeks’ are the estimates from themodel at the 48-week time point).
It also allows for covariate adjustment (baseline value, treatment,
visit, treatment-by-visit interaction, baseline-by-visit interaction)
and stratification (inhaled antibiotics (yes or no), baseline age (un-
der 18 versus 18 years and over), and baseline % predicted FEV
(40% up to 65% versus 65% and up to 90%)).
In future updates, if we identify any trials which report time-to-
event outcomes, we will use measures of survival analysis, and re-
port hazard ratios (HR) and 95% CIs between different arms of
the trial. Futhermore, if different trials do not report change data,
but instead present absolute post-treatment data without baseline
data (so it is not possible to calculate change data) we will use ab-
solute post-treatment data instead of change from baseline. How-
ever, if the report presents baseline and post-treatment data for
any outcome, we will calculate SDs for the change from baseline,
for example if the CI is available. When there is not enough in-
formation available to calculate the SDs for the changes, we aim
to impute them from other trials in the review where the data are
available and trials are similar (i.e. whether the trials used the same
measurement scale, had the same degree of measurement error and
had the same time periods between baseline and final value mea-
surement). If neither of these methods are possible, we will im-
pute a change-from-baseline SD from another trial, making use of
an imputed correlation co-efficient (following methods described
in chapter 16 in the Cochrane Handbook of Systematic Reviews of
Interventions (Higgins 2011b).
Unit of analysis issues
Within this review, we only included results from RCTs of parallel
design in which randomised the individual trial participants. We
also reviewed cross-over trials on an individual basis; however, we
could not extract data from the first arm and hence we excluded
them. We did not identify any cluster RCTs. In future updates,
we will exclude cluster RCTs, as this is not an appropriate study
design for this type of intervention.
Dealing with missing data
In order to allow an intention-to-treat analysis, we extracted data
on the number of participants with each outcome event, by al-
located treated group, irrespective of compliance and whether or
not the participant was later thought to be ineligible or otherwise
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excluded from treatment or follow up.We recorded the number of
participants with outcome data and checked if this was consistent
with the number of originally randomised participants. If any data
were missing or unclear, we contacted the primary investigators
for clarification. Specifically we have contacted the authors of one
excluded cross-over trial on two occasions asking if data are avail-
able from the first arm of the trials and if so requesting that the
investigators share these with us (Pradal 2002). To date we have
not received a response from the authors; however, if the first-arm
data from these trials are made available to us in the future we will
re-assess this trial for inclusion. We also contacted the authors of a
second cross-over trial and were informed that the data are held by
PTC Therapeutics and we are contacting the company for further
clarification; this trial is currently listed as ’Awaiting assessment’ (
Sermet-Gaudelus 2010).
Assessment of heterogeneity
Since we only included a single trial, we did not need to assess
heterogeneity. If we are able to include more trials in future up-
dates of the review, we will assess heterogeneity through a visual
examination of the combined data presented in the forest plots,
and by considering the I² statistic (Higgins 2003) together with
Chi² values and their CIs (Deeks 2011). This reflects the likeli-
hood that variation of results across trials are due to heterogeneity
rather than chance, and we will interpret this statistic using the
following simple classification:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
In order to identify selective outcome reporting,where possible, we
compared outcomes defined in the protocol with those reported
in the full publication. We explored the protocol of the identified
trial found on the aforementioned clinical trials registries for evi-
dence of selective reporting bias. In future, if the protocol for an
included trial is not available publicly we will contact the primary
investigators, corresponding author(s), or relevant pharmaceutical
company for a copy. We also compared outcomes listed in the
’Methods’ section of the final paper with those presented in the
’Results’ section. For negative findings that were reported either
only partially, or not at all, we contacted primary investigators for
these data, which included: CFQ-R score; weight; BMI; relative
change in FVC; adverse events that lead to interruption of treat-
ment; grading classification of adverse events; hospitalisations; ex-
tra courses of antibiotics; and disruptions to school or work atten-
dance. We did not receive a reply.
Weplanned to assess publicationbias by constructing and assessing
the symmetry of a funnel plot. This would have been possible if
we included more than 10 trials in the review.
Data synthesis
As only one trial was eligible for inclusion, we were not able to
conduct a meta-analysis. We have presented the results in graphs
using the fixed-effects model. In future updates, if we are able to
include further trials, we aim to use a random-effects model to
analyse the data, regardless of the value of the I² statistic.
Subgroup analysis and investigation of heterogeneity
We planned to investigate any heterogeneity that we identified
using subgroup analyses of potential confounding factors, if suf-
ficient numbers (at least 10 trials) were available. For this review,
we planned that these confounding factors would be:
• age (children (defined as younger than 18 years of age)
versus adults);
• gender;
• intervention used.
We did not plan any subgroup analyses by antibiotic use; how-
ever, the included trial presented a post hoc subgroup analysis by
inhaled tobramycin use, which we have reported in the Results
section below. An ongoing trial excludes participants who are us-
ing long-term inhaled aminoglycosides within the preceding four
months. This difference in participant baseline characteristics is
also a potential confounding factor for future updates.
The analysis in this review is based on aggregate data as we have
no individual participant data. We will incorporate such analysis
in future updates if these data are available.
Sensitivity analysis
If we had been able to combine a sufficient number of trials (at least
10), we planned to examine the impact of risk of bias on the results
examined by comparing meta-analyses including and excluding
trials with concerns of high risk of selection or reporting bias due
to issues relating to randomisation, allocation concealment, or
masking of interventions from participants or trial personnel.
Summary of findings and quality of evidence
(GRADE)
We specified in our protocol that we would present three tables:
the first for outcomes measured up to one month; the second for
outcomes between one and six months; and the third for longer
term outcomes over six months. We felt that data from previous
trials and reviews (Sinha 2014; Patel 2015) highlight the potential
for a rapid response to this type of intervention and planned to
present these in the first table, but were also interested in illus-
trating evidence of a sustained response in the short to medium
term, as we feel this is important for stakeholders and aimed to
present such data in the second table. At present, data for short-
and medium-term outcomes are not available, therefore we have
presented a summary of findings table for longer-term outcomes.
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As planned, we have presented the following outcomes in a
summary of findings table: QoL, respiratory function measures
(FEV ), adverse events, pulmonary exacerbations; nutrition and
growth; and sweat chloride level. In a post hoc change we have
also added the outcome of mortality.
We determined the quality of the evidence using the GRADE ap-
proach; and downgraded evidence in the presence of a high risk of
bias in at least one trial, indirectness of the evidence, unexplained
heterogeneity or inconsistency, imprecision of results, high prob-
ability of publication bias. We downgraded the evidence by one
level if the limitation was considered to be serious and by two
levels if very serious. Under the GRADE approach, evidence may
have been upgraded if a large treatment effect was demonstrated
with no obvious biases or if a dose-response effect exists.
R E S U L T S
Description of studies
Please see the tables (Characteristics of included studies;
Characteristics of excluded studies; Characteristics of ongoing
studies).
Results of the search
The search of the Group’s Cystic Fibrosis Trials Register identified
a total of 24 publications (abstracts and full papers) representing
six trials. The search of the online clinical trials registries identi-
fied two ongoing trials (McIntosh 2014a; McIntosh 2014b) and
two additional references to trials found through the initial search
of the Group’s register. One trial was included (13 references)
(Kerem 2014) and five trials (11 references) were excluded (Kerem
2008;McIntosh 2014b; Pradal 2002; Romano 2000;Wilschanski
2003). One cross-over trial is currently awaiting assessment until
we are able to obtain clarification of data (Sermet-Gaudelus 2010)
and one trial (one reference) is ongoing and potentially eligible
for inclusion (McIntosh 2014a). The results of the search are dis-
played in the PRISMA diagram below (Figure 1). No additional
trials were identified by screening references of included trials or
by contacting authors of included trials, leaders in the field, and
companies known to be developing and investigating ataluren and
similar compounds.
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Figure 1. Study flow diagram.
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Included studies
We included one trial (13 references) with 238 participants; the
trial was available as full text (Kerem 2014).
Trial design
The included trial was a RCT of parallel design and PTC Thera-
peutics Incorporatedwas the responsible funding body. TheCystic
Fibrosis Foundation, the Food and Drug Administration’s Office
of Orphan Products Development and the National Institutes of
Health (NIH) were also involved in providing grant support to
the trial.
This phase 3 trial had two-arms and lasted 48 weeks. Participants
who completed 48 weeks of treatment were entered into an on-
going open-label extension study which is planned to last up to
96 weeks (McIntosh 2014b). Participants from this extension trial
are not eligible for inclusion in this review as they were not re-
randomised to treatment or control.
The included trial was conducted at multiple centres, recruiting
participants from 36 sites in 11 countries in North America and
Europe (Kerem2014).Outcome datawere reported at time frames
ranging from 8 to 48 weeks.
Participants
All 238 participants (118 male, 114 female) had a confirmed di-
agnosis of CF with documentation of the presence of a nonsense
mutation in at least one allele of the CFTR gene. The trial re-
cruited participants aged six years and over (mean age of 23 years).
Participants were allocated in a 1:1 ratio to either intervention or
placebo and were stratified according to age (under 18 years ver-
sus 18 years and over), chronic inhaled antibiotic use (yes versus
no) and % predicted FEV (40% up to 65% versus 65% up
to 90%). All participants had a baseline FEV of 40% or over
for age, gender and height. The baseline characteristics presented
were similar in the intervention and the placebo arms, with no
statistical difference seen between the two arms (Kerem 2014).
Interventions
Ataluren (administered as a powdered oral suspension) was the
intervention drug used in the included trial. The trial compared
a three-times daily regimen of ataluren (10mg/kg in the morning,
10 mg/kg at mid-day and 20 mg/kg in the evening) to placebo.
Participants continued on prescribed medications that were ap-
proved for CF during the trial period (Kerem 2014).
Outcomes
The primary endpoint for this trial was the relative change in %
predicted FEV from baseline to week 48 as assessed by spirom-
etry. The trial used the CFQ-R respiratory domain to measure
QoL and reported on the mean change in the score from baseline
to week 48 in the supplementary text. The trial reported on the
safety profile of ataluren and the pulmonary exacerbation rate us-
ing the modified Fuchs’ definition. The change in total lung CT
scores and sub-scores was presented in the trial. The trial also re-
ported the absolute difference in change in sweat chloride concen-
tration from baseline between the two treatment arms. The trial
reported on the difference in change from baseline for BMI and
body weight between the two groups. Nasal potential difference,
a tertiary endpoint, was not included in this review as it is not yet
a validated outcome (Kerem 2014).
Excluded studies
We excluded five trials (11 references) (Characteristics of excluded
studies). One of these trials was of cross-over design and data
from the first treatment arm could not be extracted independently
(Pradal 2002). We have contacted the investigators of this trial
requesting the relevant data, but to date it has not been made
available to us. If in future, we are able to access the first-arm data,
we will re-assess these trials for inclusion. One trial was excluded
as it reported on the mechanism of action of the intervention and
not on the clinical benefit (Wilschanski 2003).
Three additional trials were excluded: a phase II trial did not ran-
domise participants to treatment and also entered participants into
an open-label extension trial where again, participants were not
randomised to control or to treatment (Kerem 2008); a second
trial did not randomise to treatment and used participants ho-
mozygous for deltaF508 mutations as the control group, which
was inappropriate for inclusion in this review (Romano 2000); the
final trial (still ongoing) is an open-label extension of the included
trial, where participants are not re-randomised and all participants
receive the same treatment (McIntosh 2014b).
Studies awaiting assessment
One trial is currently listed as ’Awaiting assessment’ (Sermet-
Gaudelus 2010); the lead investigator has confirmed that the data
belong to PTC Therapeutics Incorporated and we are contacting
them for further details. Further details are available in the tables
(Characteristics of studies awaiting classification).
Trial design
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This is a multicentre (three centres across France and Belgium),
randomised two-arm cross-over trial consisting of two cycles of 14
days on and 14 days off treatment.
Participants
The trial enrolled 30 participants with CF and nonsense muta-
tions over the age of six years and up to the age of 18 years, with
approximately equal numbers of males and females.
Interventions
The trial compared ataluren (as a powdered oral suspension) taken
three times per day at either a lower dosing regimen (4 mg/kg in
morning, 4 mg/kg at midday, 8 mg/kg in evening) or a higher
dosing regimen (10 mg/kg in the morning, 10 mg/kg at midday,
20 mg/kg in the evening). The order of the cycles was randomised.
Outcomes
The trial’s primary outcome was CFTR chloride transport (mea-
sured by nasal TEPD). Secondary outcomes included ion channel
activity, proportion of cells showing atypical CFTR protein ex-
pression, disease-related clinical parameters (FEV , FVC, body
weight), safety, compliance, pharmacokinetics and adverse events.
Ongoing studies
One trial is ongoing (McIntosh 2014a). For further details please
see the table (Characteristics of ongoing studies).
Trial design
The trial is anRCTof parallel design funded by PTCTherapeutics
Incorporated. This phase 3 trial has two arms and is planned to
last 48 weeks (expected completion date is November 2016).
Participants
Participants aged six years and over are being recruited from 88
sites over 16 countries in North America, Europe and Australa-
sia (expected enrolment is 208 participants). Inclusion criteria in-
clude (but not limited to): sweat chloride over 60 mEq/L; demon-
stration of an FEV more than or equal to 40% and less than or
equal to 90% of predicted; and documentation of the presence of
a nonsense mutation in at least one allele of the CFTR gene. Of
note, this trial states that participants who are using long-term in-
haled aminoglycosides (e.g. tobramycin) or have received inhaled
aminoglycosides in the four months prior to screening are to be
excluded from the trial.
Interventions
Ataluren (as a powdered oral suspension) taken three times per
day (10 mg/kg in the morning, 10 mg/kg at midday and 20 mg/
kg in the evening) will be compared to matched placebo for 48
weeks.
Outcomes
The primary endpoint for this ongoing trial is FEV at 48 weeks
assessed by spirometry. Secondary outcome measures include the
rate of pulmonary exacerbations using modified Fuchs’ criteria;
respiratory QoL as assessed by the CFQ-R respiratory domain;
and body weight and BMI.
Risk of bias in included studies
A graphical summary of the risk of bias assessments for the in-
cluded trial is presented in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Sequence Generation
The included trial reported that the randomisation code was ex-
ternally generated using a small block size, stratified by age (under
18 years versus 18 years and over), chronic inhaled antibiotic use
(yes versus no), and % predicted FEV (40% up to 65% versus
65% up to 90%). We judged the trial to have a low risk of bias for
sequence generation (Kerem 2014).
Allocation Concealment
Participants in the included trial were allocated to ataluren or
placebo using interactive response technology according to the
concealed randomisation list and we judged the risk of bias for
allocation concealment to be low (Kerem 2014).
Blinding
The trial reported on blinding of trial personnel to treatment as-
signments including medical and ancillary staff, the trial investi-
gators and the sponsor (Kerem 2014). The trial specifically stated
that only designated personnel at the contract research organisa-
tion had access to the treatment assignments, therefore we judged
the trial to have a low risk of bias with regards to blinding of
personnel. The trial stated that participants were blinded to treat-
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ment assignment and that the placebo was identical in appearance
to the active drug.Although it did not refer to the consistency or
taste of the orally administered powder for suspension, we judge
the trial to have a low risk of bias with regards to the blinding of
participants (Kerem 2014).
Incomplete outcome data
Attrition was low (less than 15%) in the included trial; a total of 20
participants from the ataluren group and 14 participants from the
placebo group withdrew from the trial (P = 0.36). Six participants
(four from the ataluren and two from the placebo group) were
excluded prior to week 8 as they did not have valid post-baseline
spirometry. These participants were not included in the intention-
to-treat population. There were 116 participants in the intention-
to-treat population in each treatment arm. After week 8, 16 par-
ticipants from the ataluren group withdrew from the trial: seven
due to an adverse event; one participant was lost to follow up; nine
withdrew consent; one due to investigator decision; one due to
protocol non-compliance; and one withdrew for ’other’ reasons.
At this time, 12 participants from the placebo group withdrew
from the trial: two due to an adverse event; nine withdrew consent;
one due to protocol non-compliance; and two for ’other’ reasons.
The investigators reported the followingmissing values: 12% (104
out of 840) in the ataluren treatment group and 9% (73 out of
820) in the placebo group. The following missing data from the
ataluren group were found by review authors: one participant’s to-
tal lung CT score at week 48; and three participants change from
baseline in sweat chloride concentration. In the placebo group,
missing data were: one participant was reported by investigators to
have a missing FEV at week 48 and was excluded from the per-
protocol population analysis; and seven participants change from
baseline in sweat chloride concentration was found to be missing
by review authors. We therefore judged there to be a low risk of
bias due to incomplete outcome data.
Selective reporting
The protocol for the included trial was found through the online
clinical trials registries database (NCT00803205). The following
outcomes were included in the protocol, but not reported in the
full publication: ataluren (PTC124) pharmacokinetics; antibiotic
use and hospitalisation due to CF-related symptoms; and disrup-
tions to school or work due to CF-related symptoms. For QoL,
weight and BMI, the trial reported no significant difference in
mean change from baseline between treatment arms but did not
state either baseline and week 48 data, or the change from baseline
in each group to allow further analysis. Regarding adverse events,
the trial reported adverse events that occurred in more than 10%
of the population and the adverse events that lead to discontin-
uation of treatment. The trial did not report whether an adverse
event led to the interruption of treatment. By not reporting the
aforementioned information, the trial is at high risk of selective
outcome reporting.
The trial investigators undertook a post hoc subgroup analysis
of participants depending on their use of chronic inhaled antibi-
otics; however, they only reported findings for selected outcomes
in that subgroup (relative change from baseline in FEV , abso-
lute values for FEV , pulmonary exacerbation rate and total lung
CT scores). The investigators selectively reported data for partici-
pants who were or were not receiving inhaled tobramycin, and did
not report data for other inhaled antibiotics. Absolute values for
FEV at baseline and week 48 were presented for the subgroup of
participants who were not receiving chronic inhaled tobramycin,
highlighting favourable results for ataluren in this particular group
of participants. The trial did not report complete data to allow
analysis (i.e. baseline/week 48/change from baseline) for non-sig-
nificant outcomes, including total lung CT scores by subgroup
and relative change from baseline in FEV in participants on
long-term inhaled tobramycin, and instead stated that there was
no significant difference between treatment arms. Due to selec-
tively reporting the findings of the subgroup of participants who
were not receiving chronic inhaled tobramycin, we judge the trial
to be at high risk of bias.
Other potential sources of bias
The baseline characteristics of participants in the treatment arms
was similar. Median rate of compliance was based on trial drug
accountability and was reported to be approximately 90% for
ataluren compared to approximately 85% for placebo (Kerem
2014).
Kerem undertook a post hoc subgroup analysis of participants by
chronic inhaled antibiotic use. This was not a subgroup that we
planned to report on, but we have presented the results directly
from the paper within our results below. The rationale for doing
this analysis in the trial is not entirely clear; the investigators hy-
pothesised that aminoglycosides, including inhaled tobramycin,
interfere with ataluren at a ribosomal level. Kerem’s post hoc in
vitro study demonstrated that aminoglycosides (tobramycin or
gentamicin) reduce ataluren’s ability to read-through the PTC,
and that this effect was not seen with the other tested inhaled an-
tibiotics, colistin or aztreonam (Kerem 2014). There is no further
scientific evidence for such an effect.
Effects of interventions
See: Summary of findings for the main comparison
Ataluren versus placebo
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Primary outcomes
1. Quality of life
a. total QoL score
The included trial did not report on total QoL scores.
b. different sub-domains
The trial reported on the CFQ-R respiratory domain scores. It
did not report absolute data at baseline and week 48; however,
it did report on the mean change in CFQ-R respiratory domain
scores from baseline to week 48. The reported difference in the
mean changes between ataluren and placebo was 2.9 for the age
group 6 to 13 years age and 0.5 for participants aged 14 and over,
neither of which were statistically significant (P = 0.8152 and P =
0.3723 respectively). We were unable to conduct analyses due to
insufficient data provided.
2. Respiratory function measures (litres or % predicted for
age, sex and height)
a. FEV
(relative change from baseline)
Data were available for the relative change from baseline in %
predicted FEV at up to 48 weeks and also in graphical format
at eight-weekly intervals (8, 16, 24, 32 and 40 weeks). At up to
48 weeks, both treatment arms showed a decline in mean relative
change from baseline in FEV , the difference of which was not
significant, MD 2.97% (95% CI -0.58 to 6.52) (P = 0.10). Us-
ing data deduced from the graph (figure 2 in full paper) (Kerem
2014), at eight weeks we found a significant benefit for ataluren
compared to placebo, estimated MD 3.50 (95% CI 0.86 to 6.14)
(P = 0.009). At the remaining time points, we demonstrated no es-
timated significant difference between treatment groups (Analysis
1.1).
Subgroup analysis
In Kerem’s post hoc subgroup analysis of participants by chronic
inhaled antibiotic use, in the subgroup of participants who did not
receive chronic inhaled tobramycin, the trial reported a significant
difference in the decline in mean relative change from baseline in
FEV at up to 48 weeks in the ataluren arm compared to placebo,
MD 5.7% (95% CI 1.71 to 9.69) (P = 0.005) (Analysis 1.2)
(Kerem2014). At 8, 32 and 40 weeks, Kerem showed an estimated
significant benefit for ataluren compared to placebo, MD 5.70
(95% CI 2.21 - 9.19) (P=0.001), 5.40 (95% CI 1.08 - 9.72) (P=
0.01) and 4.00 (95% CI 0.03 - 7.97) (P=0.05) respectively. There
was an estimated non-significant treatment difference at weeks 16
and 24, MD 1.40 (95% CI -1.94 to 4.74) (P = 0.41) and MD
1.80 (95% -2.52 to 6.12) (P = 0.41) respectively (data estimated
from figure 3 in full paper) (Analysis 1.2) (Kerem 2014).
In the subgroup of participants whowere receiving chronic inhaled
tobramycin, Kerem reported a non-significant treatment differ-
ence at up to 48 weeks, MD -1.60% (95% CI -8.15 - 4.95) (P =
0.63). There was an estimated significant difference at 24 weeks in
the subgroup of participants receiving chronic inhaled tobramycin
which favoured placebo, MD -6.80 (95% CI -12.35 to -1.25) (P
= 0.02) and no estimated significant treatment difference at each
of the other eight-weekly time points in this subgroup (data esti-
mated from figure 3 in full paper) (Analysis 1.3) (Kerem 2014).
b. FEV
absolute values
The trial reported on FEV absolute values at baseline and at
week 48 and reported no significant difference in baseline FEV
between the ataluren and placebo treatment arms. There was no
statistical difference in mean change from baseline at week 48
between treatment groups, MD 1.76% (95% -0.43 to 3.95) (P =
0.12) (Analysis 1.4) (Kerem 2014).
Subgroup analysis
In Kerem’s subgroup analysis, there was a reduction in the decline
inmean absolute change in FEV in the ataluren group compared
to the placebo group,MD3.40% (95%CI 0.75 to 6.05) (P = 0.01)
in participants not taking chronic inhaled tobramycin (Analysis
1.5) (Kerem 2014). No data for mean absolute change in FEV
was reported for participantswhowere receiving long-term inhaled
tobramycin.
c. FVC (absolute values and relative change from baseline)
Estimates for mean relative change from baseline in FVC at each
eight-weekly time point, including week 48, have been deduced
from graphical representation (supplementary figure 1 of the pa-
per) (Kerem 2014). There was no estimated statistical difference
in the mean relative change from baseline in FVC at any time
point (8, 16, 24, 32, 40 or 48 weeks), MD at 48 weeks 1.10 (95%
CI -1.97 to 4.17) (P = 0.48) (Analysis 1.6) (Kerem 2014).
3. Adverse events
The investigators classified adverse events by severity as grade 1
(mild), grade 2 (moderate), grade 3 (severe) and grade 4 (life-
18Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
threatening or death); however, they did not specify the criteria for
grade 1 to 3 classifications. It was not possible for review authors to
determine which reported adverse events they would class as mild
(therapy does not need to be discontinued) or moderate (therapy
is discontinued, and the adverse effect ceases). The trial reported
on adverse events which required discontinuation of therapy un-
der the heading ’severe (life-threatening or debilitating, or which
persists even after treatment is discontinued)’.
In the included trial, more participants in the placebo group ex-
perienced diarrhoea, nausea, pyrexia, upper respiratory tract in-
fections, rhinitis, pulmonary exacerbations, cough, haemoptysis
and oropharyngeal pain compared to participants in the ataluren
group. Abdominal pain, vomiting, sinusitis, headache and pro-
ductive cough occurredmore in participants in the ataluren group.
Regarding statistically significant adverse events, oropharyngeal
pain was less common in the ataluren group, RR 0.28 (95% CI
0.10 to 0.83). A significantly higher number of participants in the
ataluren group reported episodes of acute kidney injury (includes
reported terms including renal failure, acute renal failure, renal
impairment, and hypercreatininaemia), RR 17.70 (99% CI 1.28
to 244.40) (Analysis 1.7) (Kerem 2014).
a. mild (therapy does not need to be discontinued)
Investigators reported fewer grade 1 (mild) adverse events in the
ataluren group compared to placebo, which was not significant
RR 0.88 (95% 0.49 to 1.57) (P = 0.66) (Analysis 1.8) (Kerem
2014).
b. moderate (therapy is discontinued, and the adverse effect
ceases)
The trial reported a non significant difference in grade 2 adverse
events between the ataluren group compared to placebo, RR 1.21
(95% 0.99 to 1.49) (P = 0.06) (Analysis 1.8) (Kerem 2014).
The trial did not report on adverse events that specifically required
interruption of treatment.
c. severe (life-threatening or debilitating, or which persists
even after treatment is discontinued)
The trial reported that eight participants from the ataluren group
and three participants from the placebo group discontinued ther-
apy due to adverse events. The difference between treatment
groups in investigator-defined grade 3 (severe) adverse events was
not significant, RR 0.62 (95% CI 0.37 to 1.03) (P = 0.07) (par-
ticipants may have had more than one adverse event) (Analysis
1.8) (Kerem2014). There were no life-threatening events reported
(Kerem 2014).
Secondary outcomes
1. Survival
a. time to event (death or lung transplant)
Zero deaths were reported and the trial did not report on lung
transplant (Kerem 2014).
b. mortality rate
The trial reported zero deaths in both treatment groups (Kerem
2014).
2. Hospitalisation
No data were reported for hospitalisation (Kerem 2014).
3. School or work attendance
The trial did not report on school or work attendance (Kerem
2014).
4. Extra courses of antibiotics
No data were reported for extra courses of antibiotics (Kerem
2014).
5. Pulmonary exacerbations
This trial reported both on physician-defined (based on the in-
dividual physician’s judgement) and protocol-defined pulmonary
exacerbation rate (assessed using modified Fuchs’ criteria). These
criteria defined a pulmonary exacerbation as four of the following
12 symptoms, with or without treatment with antibiotics: change
in sputum; new or increased haemoptysis; increased cough; in-
creased dyspnoea; fatigue; temperature over 38°C; anorexia; sinus
pain; change in sinus discharge; change in physical examination of
the chest; decrease in pulmonary function by 10% or more from
a previously recorded value; or radiographic changes indicative
of pulmonary infection (Fuchs 1994). No significant treatment
difference was found between ataluren and placebo for either the
physician- or protocol-defined pulmonary exacerbation rate at up
to 48 weeks, MD -0.02 (95% CI -0.67 to 0.63) and -0.36 (95%
CI -0.89 to 0.17) respectively (Analysis 1.9) (Kerem 2014).
Subgroup Analysis
In Kerem’s subgroup analysis they reported a significant reduction
in the protocol defined pulmonary exacerbation rate in partici-
pants not taking chronic inhaled tobramycin, MD -0.76 (95%
CI -1.51 to -0.01) compared to a higher rate in those receiving
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chronic inhaled tobramycin, which was not significant 0.36 (95%
CI -0.28 to 1.00) (Analysis 1.10) (Kerem 2014).
Participants receiving chronic inhaled tobramycin appeared to
have a reduced rate of pulmonary exacerbation compared to those
not receiving chronic inhaled tobramycin, suggesting that to-
bramycin may have a treatment effect, possibly as a result of some
correction of the underlying defect (Kerem 2014).
6. Radiological measures of lung disease
a. chest radiograph score
The included trial did not report on chest radiograph score.
b. computerised tomogram (CT) score
The included trial reported on baseline, end of treatment (ap-
proximately 48 weeks) and change from baseline in total lung CT
scores and subscores. The difference in mean change in total lung
CT score was not significant at up to end of treatment (approx-
imately 48 weeks), MD -0.28 (95% CI -0.68 to 0.12) (Analysis
1.11) (Kerem 2014).
Subgroup Analysis
Kerem reported no significant difference between ataluren and
placebo in changes in total lung CT scores in their subgroup anal-
ysis by inhaled tobramycin use (Kerem 2014). Data were not re-
ported for analysis.
7. Acquisition of respiratory pathogens
The included trial did not report on this outcome.
8. Eradication of respiratory pathogens
No data was reported for eradication of respiratory pathogens.
9. Nutrition and growth
a. weight
The trial reportedno statistical difference in change in bodyweight
between ataluren and placebo over 48 weeks (difference = 0.04
kg). Insufficient data were presented for inclusion in our analysis
(Kerem 2014).
b. BMI
Aswith weight, the trial reported no statistical difference in change
in BMI between treatment groups over 48 weeks (difference = -
0.108); further baseline and week 48 data were not reported to
allow analysis (Kerem 2014).
c. height
Height was not reported in the trial (Kerem 2014).
10. Sweat chloride
The trial reported a non-significant difference in change from
baseline in sweat chloride between ataluren and placebo at up to
48 weeks, MD-0.70 (95% CI -3.41 to 2.01) (P = 0.61) ( Analysis
1.12) (Kerem 2014).
11. Cost effectiveness (cost utility assessed as comparison of
impact on quality of adjusted life years)
The trial did not report on the cost of ataluren treatment for people
with CF (Kerem 2014).
D I S C U S S I O N
Summary of main results
This review examines whether specific therapies for class I muta-
tions (premature termination codons (PTCs)) improve clinically
relevant outcomes in people with cystic fibrosis (CF). Our search
identified 28 references for eight trials; six trials were excluded
(three cross-over trials and three non-randomised trials), one trial
is ongoing and one trial was included. The included randomised
controlled trial (RCT) of parallel design enrolled 238 participants
aged six years and over (range 6 to 53 years old) with documenta-
tion of the presence of a nonsense mutation in at least one allele of
the cystic fibrosis transmembrane conductance regulator (CFTR)
gene. The trial compared 40mg/kg/day (in divided doses) of orally
administered ataluren to placebo for a duration of 48 weeks. The
trial was assessed as low risk for selection and attrition bias, unclear
risk for performance bias and high risk for selective reporting.
Ataluren was no better than placebo for the review’s primary or
secondary outcome measures at up to 48 weeks. The trial did not
report a significant difference inCFQ-R respiratory domain scores
between treatment groups for either the 6 to13 year-old age group
or for those aged 14 years and over. There was no significant im-
provement in respiratory function measures (relative or absolute
change in forced expiratory volume at one second (FEV ) and
relative change in forced vital capacity (FVC)) at up to 48 weeks
in participants treated with ataluren. We were unable to report on
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mild or moderate adverse events as defined by the review’s pro-
tocol. Reduced reports of oropharyngeal pain were recorded in
the ataluren group, risk ratio (RR) 0.28 (95% CI 0.10 to 0.83).
Ataluren was associated with a significantly higher rate of episodes
of acute kidney injury (includes reported terms including renal
failure, acute renal failure, renal impairment, and hypercreatini-
naemia) RR 17.70 (99% CI 1.28 to 244.40). The adverse events
profile of ataluren should be interpreted with caution as it was
based on small numbers of participants and the trial was not pow-
ered to assess this outcome.
The trial reported no significant reduction in pulmonary exacer-
bation rates (either physician- or protocol-defined) or sweat chlo-
ride concentration in the ataluren group compared to the placebo
group. Furthermore, there was no significant difference in change
in total lung computer tomography (CT) score, body weight or
body mass index (BMI) over 48 weeks.
No deaths were reported in either treatment group and the length
and size of the trial precluded valid assessment of the impact of
ataluren on survival. An open-label extension trial of this phase 3
RCT is ongoing and although not eligible for full inclusion due to
lack of randomisation and control, we aim to review results with
regards to survival data.
The trial investigators undertook a post hoc subgroup analysis of
participants not receiving chronic inhaled tobramycin (n = 146)
which demonstrated favourable results for ataluren. They reported
a reduction in the decline in FEV over 48 weeks in participants
treated with ataluren (n = 72, compared to placebo, n = 74, MD
5.7% (95% CI 1.71% to 9.69). Additionally, in this subgroup
of participants, those treated with ataluren were seen to have sig-
nificant reduction in pulmonary exacerbation rates (protocol-de-
fined), MD -0.76 (95% CI -1.51 to -0.01).
Some aminoglycosides, including tobramycin and gentamicin,
have previously been demonstrated to have the ability to mask the
abnormal gene sequence, resulting in significant changes of the salt
transporting defect towards normal (Clancy 2001; Howard 1996;
Wilschanski 2003). The mechanism of action for such aminogly-
cosides is thought to be similar to that of ataluren, in that they
enable read-through of class I mutations (PTCs) (Welch 2007). It
is possible that Kerem’s subgroup of participants receiving chronic
inhaled tobramycin may have been exposed to read-through from
the aminoglycoside and therefore they would not further benefit
from ataluren.
Overall completeness and applicability of
evidence
The included trial recruited a mixture of adults and children with
CF with nonsense mutations across 36 sites internationally. The
mean age was 23 years of age with 32% of participants aged under
18 years of age and the remaining participants aged 18 years and
over. Nonsense mutations are a type of class I mutation (PTC)
and the results can be assumed be applicable to individuals with
nonsense CF mutations not included in this trial. Of note, how-
ever, is that the current trial did not enrol participants aged under
six years of age, pregnant women or those with stop codon muta-
tions (another form of class I mutations (PTCs)). There are insuf-
ficient data for outcomes which we considered important for this
review: hospitalisation, school or work attendance, extra courses
of antibiotics, chest radiograph score, acquisition or eradication
of respiratory pathogens and cost effectiveness.
Kerem’s post hoc analysis of the subgroup of participants not re-
ceiving chronic inhaled tobramycin only reported on results for
specific outcomes (absolute and relative change in % predicted
FEV from baseline, pulmonary exacerbation rate and total lung
CT scores). Results for this subgroupwere not available for two out
of three of this review’s primary outcomes (quality of life (QoL)
and adverse events).
Quality of the evidence
Please see section in table (Summary of findings for the main
comparison). The trial was an RCT which represents the highest
quality with regards to trial design. The trial included a total of
238 participants and was well-powered for the primary outcome
(relative change in % predicted FEV ). The randomised phase
of the trial lasted 48 weeks and participants have been entered
into an open-label extension trial due to last 96 weeks (open-label
extension results not included in this review). The overall risk of
bias was judged to be moderate with well-documented random
sequence generation, allocation concealment and blinding of trial
personnel. Blinding of participants was less clear, as details of orally
administered placebo compared to ataluren (such as taste and con-
sistency) were not provided. The risk of selective reporting was
generally high as the trial did not always report on outcomes out-
lined in the protocol, present data for all outcomes and report on
outcomes considered important by the review authors. The trial
was sponsored by the manufacturer of ataluren, PTC Therapeu-
tics Incorportated. Some trial authors declared a financial interest:
eight out of 27 authors are employees of PTC Therapeutics Incor-
portated and hold financial interests in the company; two authors
received compensation for consultant services from PTC Thera-
peutics Incorportated during the trial; and four authors received
compensation for travel expenses for meetings related to the trial.
Overall, we judged the quality of the evidence to be moderate
(Summary of findings for the main comparison).
Potential biases in the review process
Two authors independently applied inclusion and exclusion crite-
ria to references found through a comprehensive literature search
(AA and CH). The authors then individually extracted data and
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assessed the risk of bias in the included trial. If any disagreement
had arisen on the risk of bias of the trial, we would have attempted
to reach a consensus by discussion, failing which a third author
(KWS)would have arbitrated. The analysis was undertaken by one
review author (AA). This methodological approach ensured that
risks of bias in the review process were kept to a minimum. This
review has assessed all available published trial data. Trial authors
were contacted for relevant unpublished information and individ-
ual participant data. None have been made available to date. We
are not aware of any unpublished trials, although we have high-
lighted issues with selective reporting in the included trials.
We planned to include cross-over trials if results from the first
treatment arm were available. Independently assessing the two rel-
evant cross-over trials which were identified, we were unable to
extract their data and therefore contacted the investigators. We
consequently listed one trial as ’Awaiting assessment’ until we are
able to further clarify details with PTC Therapeutics Incorporated
(owners of the data) and excluded one trial as we received no re-
sponse from the investigators. We are aware that this reduces the
number of trials we could include in the review. We acknowledge
that the primary outcome for the included trial was relative change
in % predicted FEV and therefore it may not be powered to
detect a difference in our other primary outcomes, QoL and ad-
verse events. Therefore, an absence of evidence of a difference in
QoL or for the majority of adverse events does not rule out that
ataluren may improve QoL or have a higher adverse event profile
compared to placebo.
Agreements and disagreements with other
studies or reviews
One trial was eligible for inclusion in this review. In future, should
further trials become eligible, we will update this review. An on-
going trial states that participants who are using long-term in-
haled aminoglycosides (e.g. tobramycin) or have received inhaled
aminoglycosides in the four months prior to screening are to be ex-
cluded from the trial. We will assess eligibility for this trial against
outlined criteria. This difference in participant baseline character-
istics is a potential confounding factor for future updates.
We are not aware of any other published systematic reviews of
ataluren and similar compounds (specific therapies for premature
termination codon class I mutations) for CF.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently insufficient evidence to determine the effect of
ataluren as a therapy for people with CF with class I mutations.
Ataluren was associated with a significantly higher rate of episodes
of renal impairment, the degree of which requires further infor-
mation.
Implications for research
It is important that future trials assess outcomes to determine the
long-term use of ataluren in terms of both efficacy and tolerability.
Future trials should be powered to detect a difference not only
in relative change from baseline in FEV but also in QoL and
adverse events; outcomes of significant importance to people with
CF. In particular, the clear reporting of adverse events is critical,
with particular attention to episodes of renal impairment. Criteria
for any grading classifications used when reporting adverse events
should be clearly stated.
Given the chronic nature of CF, it is important that the burden
of additional treatment to people’s current regimen is examined
as well as the potential impact of new therapies on adherence to
existing CF medications.
Cross-over trials should be avoided given the potential for the
treatment to change the natural history of CF. Furthermore, future
trials should be large enough to enable detailed analysis of the
effectiveness of ataluren in population subgroups, for example,
adults and children.
Currently, there are no trials comparing ataluren to treatment with
other compounds for class I mutations (PTCs) in CF. In particu-
lar, given the results of Kerem’s subgroup analysis by inhaled an-
tibiotic use, further work looking at any treatment differences of
aminoglycosides versus ataluren in people with CF with class I
mutations (PTCs) is required. At present, one ongoing study is
investigating ataluren specifically in people with CF with class I
mutations (PTCs) who are not on chronic inhaled aminoglyco-
sides (McIntosh 2014a). The rationale for undertaking a trial en-
rolling this subgroup of participants is not clear. Further research
examining the interaction of tobramycin and ataluren is required,
in particular characterising the potential of tobramycin to cause
read-through of PTCs.
Determinations of resource use and the cost of ataluren treatment
are important and ongoing health economic evaluations are re-
quired.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Kerem 2014
Methods 2-arm RCT of parallel design.
Multicentre: 36 sites.
Duration: 48 weeks.
Participants Participants with CF aged 6 years and over with a nonsense mutation in at least one
allele of the CFTR gene. A total of 238 participants were enrolled into this study
Age
Treatment group: mean (SD) 22.8 (10.18) years; median (range) 22.0 (6 - 49) years
Control group: mean (SD) 23.2 (9.32) years; median (range): 22.0 (8 - 53) years.
Age split by group
Treatment group: under 18 years n (%) 38 (32.8%); 18 years and over n (%) 78 (67.
2%)
Control group: under 18 years n (%) 37 (31.9%); 18 years and over n (%): 79 (68.1%).
Sex
Treatment group: n (%) 60 (51.7%) males, 56 (48.3%) females.
Control group: n (%) 58 (50%) males, 58 (50%) females.
Body weight
Treatment group: mean (SD) 53.5 (13.94) kg; median (range): 54.4 (21 - 105) kg.
Control group: mean (SD) 56.0 (13.15) kg; median (range): 57.2 (24 - 93) kg
% predicted FEV at baseline
Treatment group: mean (SD) 62.1 (13.62); median (range) 63.4 (38.4 - 90.3).
Control group: mean (SD) 60.2 (15.14); median (range): 59.0 (36.2 - 92.6)
Sweat chloride at baseline
Treatment group: mean (SD) 100.1 (14.22); median (range) 101.5 (22.5 - 128.0).
Control group: mean (SD) 96.6 (15.93): median (range): 100.0 (22.0 - 117.5)
Inhaled antibiotic use at randomisation
Total n (%): treatment group 64 (55.2%); control group 63 (53.4%).
Aminoglycoside (tobramycin) n (%): treatment group 44 (37.9%); control group 42
(35.6%).
Colistin n (%): treatment group 30 (25.9%); control group 22 (18.6%).
Aztreonam n (%): treatment group 10 (8.3%); control group 8 (6.8%)
Interventions Treatment group (n = 120): ataluren 3 times a day - 10 mg/kg in the morning, 10 mg/
kg at midday, 20 mg/kg in the evening.
Control (n = 118): placebo 3 times a day.
Outcomes Primary outcome measure
1. FEV *
Secondary outcome measures
1. Pulmonary exacerbation frequency*
2. Cough frequency*
3. Respiratory health related quality of life as assessed by the CFQ-R respiratory domain*
4. FVC*
5. Safety profile*
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Kerem 2014 (Continued)
6. Compliance with trial drug administration*
7. Ataluren (PTC124) pharmacokinetics
8. Antibiotic use and hospitalisation due to CF-related symptoms
9. Disruptions to school or work due to CF-related symptoms
10. Body weight*
11. Markers of lung inflammation
12. Lung computerized tomography CF score*
13. Nasal TEPD*
14. Sweat chloride concentration*
Notes PTC Therapeutics Incorporated was the responsible funding body
*These outcomes are presented in the review.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation code was externally
generated using a small block size, strati-
fied by age (<18 versus≥18 years), chronic
inhaled antibiotic use (yes versus no), and
% predicted FEV (40% to <65% versus
≥65% to 90%)
Allocation concealment (selection bias) Low risk Interactive response technologywas used to
allocate participants to ataluren or placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants were blinded to treatment;
details of consistency and taste of placebo
have not been provided
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only designated personnel at the contract
research organisation had access to the
treatment assignments. Medical and ancil-
lary staff, the trial investigators and the
sponsor were blinded to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 238 participants were randomised; 120
participants to the ataluren group and 118
participants to the placebo group
4 participants from the ataluren group and
2 from the placebo group were excluded
prior to week 8 and were excluded from the
ITT population. The ITT population in-
cluded 116 participants in each treatment
arm
16 participants withdrew from the study in
ataluren group and12 in the placebo group.
100 participants in the ataluren group and
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Kerem 2014 (Continued)
104 in the placebo group were included in
analysis (total = 204)
The review authors found minor discrep-
ancies in the number of participants anal-
ysed for the following outcome measures:
total lungCT score and sweat chloride con-
centration
Selective reporting (reporting bias) High risk Protocol located on online trials registries
database. The following outcomes were
listed in the protocol but not published:
1. Ataluren (PTC124) pharmacokinetics
2. Antibiotic use and hospitalisation due to
CF-related symptoms
3. Disruptions to school or work due to
CF-related symptoms
Subgroup analysis of participants not re-
ceiving chronic inhaled tobramycin show-
ing significant benefit for ataluren were re-
ported for FEV and pulmonary exacerba-
tions. Results for this subgroupwere not re-
ported for each outcome and results for par-
ticipants on other inhaled antibiotics were
not fully reported
Other bias Unclear risk Similar baseline characteristics and median
rate of compliance (approximately 90%
for ataluren and approximately 85% for
placebo); however, the rationale for the sub-
group is not clear and may be flawed lead-
ing to a potential source of bias
CF: cystic fibrosis
CFQ-R: cystic fibrosis questionnaire - revised
CFTR: cystic fibrosis transmembrane conductance regulator
FEV : forced expiratory volume in 1 second
FVC: forced vital capacity
ITT: intention to treat
RCT: randomised controlled trial
SD: standard deviation
TEPD: transepithelial potential difference
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Kerem 2008 Participants not controlled, randomised or blinded to treatment
McIntosh 2014b Not a randomised controlled trial; participants invited to single allocation safety trial after completing a previous
randomised controlled trial
Pradal 2002 Cross-over trial and data from first treatment arm not presented independently. Data requested, but no response
to date
Romano 2000 Controlled clinical trial: participants were not randomised or blinded to treatment. Controls stated to be par-
ticipants homozygous for deltaF508 mutations
Wilschanski 2003 Cross-over trial in which each participant served as their own control. Reported on mechanism of action of the
intervention (nasal potential difference and immunofluorescence microscopy of primary human airway cells)
which were not relevant to this review which is looking at clinical benefit
Characteristics of studies awaiting assessment [ordered by study ID]
Sermet-Gaudelus 2010
Methods Randomised controlled trial.
Cross-over design.
Duration: 2x 28-day cycles of 14-day on and 14-day off.
Location: multicentre (3 centres - 1 in France and 2 in Belgium)
Participants Children (at least 6 years old and no older than 18 years) with a nonsense mutation of CF
30 participants (16 children aged 6 - 12 years and 14 adolescents aged 13 - 18 years) enrolled, no drop outs
Age (median (range)): 12 (6 - 18) years.
Gender: 16 males, 14 females.
Interventions Ataluren in the form of vanilla flavoured granules (in aluminium foil sachets) to mix with either water, apple juice or
milk to make a suspension for oral administration
Treatment taken 3x daily with dosage based on weight, but cycles had different dosing levels. Order of dose levels
randomised
Cycle 1 (lower dosing regimen): 4 mg/kg in morning, 4 mg/kg at midday, 8 mg/kg in evening
Cycle 2 (higher dosing regimen): 10 mg/kg in morning, 10 mg/kg at midday, 20 mg/kg in evening
Outcomes Primary outcome: CFTR chloride transport (nasal TEPD).
Secondary outcomes: ion channel activity, proportion of cells showing atypical CFTR protein expression, disease-
related clinical parameters, safety, compliance, pharmacokinetics, FEV , FVC, body weight, adverse events
Notes Trial drug provided by PTC Therapeutics.
Powered to detect change in total chloride transport.
CF: cystic fibrosis
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CFTR: cystic fibrosis transmembrane conductance regulator
FEV ; forced expiratory volume in one second
FVC: forced vital capacity
TEPD: transepithelial potential difference
Characteristics of ongoing studies [ordered by study ID]
McIntosh 2014a
Trial name or title A Phase 3 Efficacy and Safety Study of Ataluren (PTC124®) in Patients With Nonsense Mutation Cystic
Fibrosis
Methods Phase 3, international, multicentre, randomised, double-blind, placebo-controlled trial of ataluren in partic-
ipants with nonsense mutation cystic fibrosis not receiving chronic inhaled aminoglycosides
Participants Participants to be recruited from 88 sites across 16 countries in North America, Europe and Australasia
Inclusion criteria include (but not limited to): age 6 years and over; sweat chloride >60 mEq/L; demonstration
of an FEV ≥ 40% and ≤90% of predicted; and documentation of the presence of a nonsense mutation in
at least 1 allele of the CFTR gene
Estimated enrolment: 208
Interventions Ataluren (PTC124®) in oral powder for suspension form taken 3 times per day (10 mg/kg in the morning,
10 mg/kg at midday and 20 mg/kg in the evening for 48 weeks
Placebo.
Outcomes Primary outcome measure
1. FEV by spirometry
Secondary outcome measures
1. Rate of pulmonary exacerbations (modified Fuchs’ criteria)
2. Respiratory health related quality of life as assessed by the CFQ-R respiratory domain
3. Body weight and BMI
Other outcome measures
1. FVC and FEF25-75 by spirometry
2. Incidence and duration of pulmonary exacerbations
3. Other health related quality of life domains as assessed by the CFQ-R
4. Concentrations of liver enzyme tests (AST, ALT, GGT)
5. Fecal calprotectin level
6. New Pseudomonas aeruginosa lung infection
7. Safety profile characterized by type, frequency, severity, timing, and relationship to study drug of treatment-
emergent adverse events, laboratory abnormalities, and ECG abnormalities
8. Trial drug compliance as assessed by quantification of unused trial drug
9. Trough ataluren plasma concentrations
Timeframe for all outcomes measures stated to be 48 weeks.
Starting date June 2014
Contact information Joseph McIntosh, MD PTC Therapeutics
Notes Estimated Study Completion Date: November 2016
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ALT: alanine aminotransferase
AST: aspartate aminotransferase
BMI: body mass index
CFQ-R: cystic fibrosis questionnaire - revised
CFTR: cystic fibrosis transmembrane conductance regulator
ECG: electrocardiogram
FEF25-75: mid expiratory flow
FEV : forced expiratory volume in 1 second
FVC: forced vital capacity
GGT: gamma-glutamyl transpeptidase
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D A T A A N D A N A L Y S E S
Comparison 1. Ataluren versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV - mean relative change
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 8 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 3.5 [0.86, 6.14]
1.2 16 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 1.5 [-1.29, 4.29]
1.3 24 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 1.5 [-1.69, 4.69]
1.4 32 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 2.8 [-0.54, 6.14]
1.5 40 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 2.3 [-1.07, 5.67]
1.6 At up to 48 weeks 1 203 Mean Difference (IV, Fixed, 95% CI) 2.97 [-0.58, 6.52]
2 FEV - mean relative change
from baseline: subgroup
analysis of participants NOT
receiving chronic inhaled
tobramycin
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 8 weeks 1 146 Mean Difference (IV, Fixed, 95% CI) 5.7 [2.21, 9.19]
2.2 16 weeks 1 146 Mean Difference (IV, Fixed, 95% CI) 1.4 [-1.94, 4.74]
2.3 24 weeks 1 146 Mean Difference (IV, Fixed, 95% CI) 1.80 [-2.52, 6.12]
2.4 32 weeks 1 146 Mean Difference (IV, Fixed, 95% CI) 5.4 [1.08, 9.72]
2.5 40 weeks 1 146 Mean Difference (IV, Fixed, 95% CI) 4.00 [0.03, 7.97]
2.6 At up to 48 weeks 1 146 Mean Difference (IV, Fixed, 95% CI) 5.7 [1.71, 9.69]
3 FEV - mean relative change
from baseline: subgroup
analysis of participants
receiving chronic inhaled
tobramycin
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 8 weeks 1 86 Mean Difference (IV, Fixed, 95% CI) 0.30 [-4.02, 4.62]
3.2 16 weeks 1 86 Mean Difference (IV, Fixed, 95% CI) 0.40 [-3.92, 4.72]
3.3 24 weeks 1 86 Mean Difference (IV, Fixed, 95% CI) -6.80 [-12.35, -1.25]
3.4 32 weeks 1 86 Mean Difference (IV, Fixed, 95% CI) -1.5 [-7.88, 4.88]
3.5 40 weeks 1 86 Mean Difference (IV, Fixed, 95% CI) -0.80 [-7.23, 5.63]
3.6 At up to 48 weeks 1 86 Mean Difference (IV, Fixed, 95% CI) -1.60 [-8.15, 4.95]
4 FEV - mean absolute change
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 At up to 48 weeks 1 203 Mean Difference (IV, Fixed, 95% CI) 1.76 [-0.43, 3.95]
5 FEV - mean absolute change
from baseline: subgroup of
participants not receiving
chronic inhaled tobramycin
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 At up to 48 weeks 1 125 Mean Difference (IV, Fixed, 95% CI) 3.40 [0.75, 6.05]
6 FVC - mean relative change
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 8 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 2.00 [-0.37, 4.37]
6.2 16 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 0.7 [-1.93, 3.33]
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6.3 24 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 1.3 [-1.69, 4.29]
6.4 32 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 1.80 [-1.53, 5.13]
6.5 40 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 1.2 [-1.79, 4.19]
6.6 At up to 48 weeks 1 232 Mean Difference (IV, Fixed, 95% CI) 1.1 [-1.97, 4.17]
7 Adverse events occurring in
greater than 10% of trial
participants
1 Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
7.1 Diarrhoea 1 238 Risk Ratio (M-H, Fixed, 99% CI) 0.61 [0.32, 1.16]
7.2 Abdominal Pain 1 238 Risk Ratio (M-H, Fixed, 99% CI) 1.18 [0.62, 2.23]
7.3 Vomiting 1 238 Risk Ratio (M-H, Fixed, 99% CI) 1.38 [0.64, 2.98]
7.4 Nausea 1 238 Risk Ratio (M-H, Fixed, 99% CI) 0.90 [0.41, 1.96]
7.5 Pyrexia 1 238 Risk Ratio (M-H, Fixed, 99% CI) 0.84 [0.47, 1.50]
7.6 Viral Upper Respiratory
Tract Infections
1 238 Risk Ratio (M-H, Fixed, 99% CI) 0.71 [0.43, 1.17]
7.7 Sinusitis 1 238 Risk Ratio (M-H, Fixed, 99% CI) 1.05 [0.53, 2.09]
7.8 Rhinitis 1 238 Risk Ratio (M-H, Fixed, 99% CI) 0.98 [0.46, 2.10]
7.9 Upper Respiratory Tract
Infection
1 238 Risk Ratio (M-H, Fixed, 99% CI) 0.41 [0.15, 1.13]
7.10 Headache 1 238 Risk Ratio (M-H, Fixed, 99% CI) 1.40 [0.75, 2.65]
7.11 Acute Kidney Injury 1 238 Risk Ratio (M-H, Fixed, 99% CI) 17.7 [2.40, 130.47]
7.12 Pulmonary Exacerbation 1 238 Risk Ratio (M-H, Fixed, 99% CI) 0.96 [0.84, 1.10]
7.13 Cough 1 238 Risk Ratio (M-H, Fixed, 99% CI) 0.73 [0.47, 1.13]
7.14 Haemoptysis 1 238 Risk Ratio (M-H, Fixed, 99% CI) 0.60 [0.30, 1.22]
7.15 Productive Cough 1 238 Risk Ratio (M-H, Fixed, 99% CI) 1.07 [0.49, 2.33]
7.16 Oropharyngeal Pain 1 238 Risk Ratio (M-H, Fixed, 99% CI) 0.28 [0.10, 0.83]
8 Severity of adverse effects of
therapy as graded by trial
authors
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Grade 1 (mild) 1 233 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.49, 1.57]
8.2 Grade 2 (Moderate) 1 233 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.99, 1.49]
8.3 Grade 3 (Severe) 1 233 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.37, 1.03]
8.4 Grade 4 (life-threatening
or death)
1 233 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Pulmonary Exacerbation Rate 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Physician Defined
Pulmonary Exacerbation Rate
1 232 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.67, 0.63]
9.2 Protocol Defined
Pulmonary Exacerbation Rate
(as defined by modified Fuchs’
criteria) overall
1 232 Mean Difference (IV, Fixed, 95% CI) -0.36 [-0.89, 0.17]
10 Protocol Defined Pulmonary
Exacerbation Rate: subgroup
analysis by chronic inhaled
tobramycin use
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 Protocol defined
pulmonary exacerbation rate
in participants not receiving
chronic inhaled tobramycin
1 146 Mean Difference (IV, Fixed, 95% CI) -0.76 [-1.51, -0.01]
10.2 Protocol defined
pulmonary exacerbation rate in
participants receiving chronic
inhaled tobramycin
1 86 Mean Difference (IV, Fixed, 95% CI) 0.36 [-0.28, 1.00]
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11 Total Lung Computerised
Tomography Score - Mean
Change From Baseline
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 At up to 48 Weeks 1 203 Mean Difference (IV, Fixed, 95% CI) -0.28 [-0.68, 0.12]
12 Sweat chloride level - change
from baseline
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 At up to 48 weeks 1 194 Mean Difference (IV, Fixed, 95% CI) -0.70 [-3.41, 2.01]
Analysis 1.1. Comparison 1 Ataluren versus placebo, Outcome 1 FEV - mean relative change from
baseline.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 1 FEV - mean relative change from baseline
Study or subgroup Ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 8 weeks
Kerem 2014 116 -1 (9.69) 116 -4.5 (10.77) 100.0 % 3.50 [ 0.86, 6.14 ]
Subtotal (95% CI) 116 116 100.0 % 3.50 [ 0.86, 6.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0093)
2 16 weeks
Kerem 2014 116 -1.4 (11.85) 116 -2.9 (9.69) 100.0 % 1.50 [ -1.29, 4.29 ]
Subtotal (95% CI) 116 116 100.0 % 1.50 [ -1.29, 4.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
3 24 weeks
Kerem 2014 116 -2.3 (12.92) 116 -3.8 (11.85) 100.0 % 1.50 [ -1.69, 4.69 ]
Subtotal (95% CI) 116 116 100.0 % 1.50 [ -1.69, 4.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
4 32 weeks
Kerem 2014 116 -2.5 (14) 116 -5.3 (11.85) 100.0 % 2.80 [ -0.54, 6.14 ]
Subtotal (95% CI) 116 116 100.0 % 2.80 [ -0.54, 6.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
5 40 weeks
Kerem 2014 116 -1.2 (15.08) 116 -3.5 (10.77) 100.0 % 2.30 [ -1.07, 5.67 ]
-20 -10 0 10 20
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Study or subgroup Ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 116 116 100.0 % 2.30 [ -1.07, 5.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
6 At up to 48 weeks
Kerem 2014 100 -2.53 (13.25) 103 -5.5 (12.56) 100.0 % 2.97 [ -0.58, 6.52 ]
Subtotal (95% CI) 100 103 100.0 % 2.97 [ -0.58, 6.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
-20 -10 0 10 20
Favours placebo Favours ataluren
Analysis 1.2. Comparison 1 Ataluren versus placebo, Outcome 2 FEV - mean relative change from
baseline: subgroup analysis of participants NOT receiving chronic inhaled tobramycin.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 2 FEV - mean relative change from baseline: subgroup analysis of participants NOT receiving chronic inhaled tobramycin
Study or subgroup Favours ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 8 weeks
Kerem 2014 72 0.8 (9.33) 74 -4.9 (12.04) 100.0 % 5.70 [ 2.21, 9.19 ]
Subtotal (95% CI) 72 74 100.0 % 5.70 [ 2.21, 9.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.20 (P = 0.0014)
2 16 weeks
Kerem 2014 72 -0.6 (11.03) 74 -2 (9.46) 100.0 % 1.40 [ -1.94, 4.74 ]
Subtotal (95% CI) 72 74 100.0 % 1.40 [ -1.94, 4.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
-10 -5 0 5 10
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Study or subgroup Favours ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
3 24 weeks
Kerem 2014 72 -0.6 (14.42) 74 -2.4 (12.04) 100.0 % 1.80 [ -2.52, 6.12 ]
Subtotal (95% CI) 72 74 100.0 % 1.80 [ -2.52, 6.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
4 32 weeks
Kerem 2014 72 0 (14.42) 74 -5.4 (12.04) 100.0 % 5.40 [ 1.08, 9.72 ]
Subtotal (95% CI) 72 74 100.0 % 5.40 [ 1.08, 9.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
5 40 weeks
Kerem 2014 72 -0.1 (14.42) 74 -4.1 (9.46) 100.0 % 4.00 [ 0.03, 7.97 ]
Subtotal (95% CI) 72 74 100.0 % 4.00 [ 0.03, 7.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
6 At up to 48 weeks
Kerem 2014 72 -0.7 (11.93) 74 -6.4 (12.64) 100.0 % 5.70 [ 1.71, 9.69 ]
Subtotal (95% CI) 72 74 100.0 % 5.70 [ 1.71, 9.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0051)
-10 -5 0 5 10
Favours placebo Favours ataluren
37Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Ataluren versus placebo, Outcome 3 FEV - mean relative change from
baseline: subgroup analysis of participants receiving chronic inhaled tobramycin.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 3 FEV - mean relative change from baseline: subgroup analysis of participants receiving chronic inhaled tobramycin
Study or subgroup Ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 8 weeks
Kerem 2014 44 -3.7 (11.28) 42 -4 (9.07) 100.0 % 0.30 [ -4.02, 4.62 ]
Subtotal (95% CI) 44 42 100.0 % 0.30 [ -4.02, 4.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
2 16 weeks
Kerem 2014 44 -2.9 (11.28) 42 -3.3 (9.07) 100.0 % 0.40 [ -3.92, 4.72 ]
Subtotal (95% CI) 44 42 100.0 % 0.40 [ -3.92, 4.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
3 24 weeks
Kerem 2014 44 -4.7 (12.6) 42 2.1 (13.61) 100.0 % -6.80 [ -12.35, -1.25 ]
Subtotal (95% CI) 44 42 100.0 % -6.80 [ -12.35, -1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
4 32 weeks
Kerem 2014 44 -6.6 (15.26) 42 -5.1 (14.91) 100.0 % -1.50 [ -7.88, 4.88 ]
Subtotal (95% CI) 44 42 100.0 % -1.50 [ -7.88, 4.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
5 40 weeks
Kerem 2014 44 -3.4 (17.25) 42 -2.6 (12.96) 100.0 % -0.80 [ -7.23, 5.63 ]
Subtotal (95% CI) 44 42 100.0 % -0.80 [ -7.23, 5.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
6 At up to 48 weeks
Kerem 2014 44 -5.6 (17.25) 42 -4 (13.61) 100.0 % -1.60 [ -8.15, 4.95 ]
Subtotal (95% CI) 44 42 100.0 % -1.60 [ -8.15, 4.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
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Analysis 1.4. Comparison 1 Ataluren versus placebo, Outcome 4 FEV - mean absolute change from
baseline.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 4 FEV - mean absolute change from baseline
Study or subgroup Ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At up to 48 weeks
Kerem 2014 100 -1.34 (8.5) 103 -3.1 (7.39) 100.0 % 1.76 [ -0.43, 3.95 ]
Subtotal (95% CI) 100 103 100.0 % 1.76 [ -0.43, 3.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
-4 -2 0 2 4
Favours placebo Favours ataluren
Analysis 1.5. Comparison 1 Ataluren versus placebo, Outcome 5 FEV - mean absolute change from
baseline: subgroup of participants not receiving chronic inhaled tobramycin.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 5 FEV - mean absolute change from baseline: subgroup of participants not receiving chronic inhaled tobramycin
Study or subgroup Ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At up to 48 weeks
Kerem 2014 62 -0.3 (7.53) 63 -3.7 (7.58) 100.0 % 3.40 [ 0.75, 6.05 ]
Subtotal (95% CI) 62 63 100.0 % 3.40 [ 0.75, 6.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
-10 -5 0 5 10
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Analysis 1.6. Comparison 1 Ataluren versus placebo, Outcome 6 FVC - mean relative change from baseline.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 6 FVC - mean relative change from baseline
Study or subgroup Ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 8 weeks
Kerem 2014 116 -0.3 (5.39) 116 -2.3 (11.85) 100.0 % 2.00 [ -0.37, 4.37 ]
Subtotal (95% CI) 116 116 100.0 % 2.00 [ -0.37, 4.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.098)
2 16 weeks
Kerem 2014 116 -0.8 (6.46) 116 -1.5 (12.92) 100.0 % 0.70 [ -1.93, 3.33 ]
Subtotal (95% CI) 116 116 100.0 % 0.70 [ -1.93, 3.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
3 24 weeks
Kerem 2014 116 -0.8 (8.62) 116 -2.1 (14) 100.0 % 1.30 [ -1.69, 4.29 ]
Subtotal (95% CI) 116 116 100.0 % 1.30 [ -1.69, 4.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
4 32 weeks
Kerem 2014 116 -1.2 (8.62) 116 -3 (16.16) 100.0 % 1.80 [ -1.53, 5.13 ]
Subtotal (95% CI) 116 116 100.0 % 1.80 [ -1.53, 5.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
5 40 weeks
Kerem 2014 116 -0.5 (8.62) 116 -1.7 (14) 100.0 % 1.20 [ -1.79, 4.19 ]
Subtotal (95% CI) 116 116 100.0 % 1.20 [ -1.79, 4.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
6 At up to 48 weeks
Kerem 2014 116 -1.5 (7.54) 116 -2.6 (15.08) 100.0 % 1.10 [ -1.97, 4.17 ]
Subtotal (95% CI) 116 116 100.0 % 1.10 [ -1.97, 4.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
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Analysis 1.7. Comparison 1 Ataluren versus placebo, Outcome 7 Adverse events occurring in greater than
10% of trial participants.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 7 Adverse events occurring in greater than 10% of trial participants
Study or subgroup Ataluren Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
1 Diarrhoea
Kerem 2014 13/120 21/118 100.0 % 0.61 [ 0.26, 1.42 ]
Subtotal (95% CI) 120 118 100.0 % 0.61 [ 0.32, 1.16 ]
Total events: 13 (Ataluren), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
2 Abdominal Pain
Kerem 2014 18/120 15/118 100.0 % 1.18 [ 0.51, 2.72 ]
Subtotal (95% CI) 120 118 100.0 % 1.18 [ 0.62, 2.23 ]
Total events: 18 (Ataluren), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
3 Vomiting
Kerem 2014 14/120 10/118 100.0 % 1.38 [ 0.50, 3.79 ]
Subtotal (95% CI) 120 118 100.0 % 1.38 [ 0.64, 2.98 ]
Total events: 14 (Ataluren), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
4 Nausea
Kerem 2014 11/120 12/118 100.0 % 0.90 [ 0.32, 2.50 ]
Subtotal (95% CI) 120 118 100.0 % 0.90 [ 0.41, 1.96 ]
Total events: 11 (Ataluren), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
5 Pyrexia
Kerem 2014 18/120 21/118 100.0 % 0.84 [ 0.40, 1.80 ]
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Study or subgroup Ataluren Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Subtotal (95% CI) 120 118 100.0 % 0.84 [ 0.47, 1.50 ]
Total events: 18 (Ataluren), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
6 Viral Upper Respiratory Tract Infections
Kerem 2014 21/120 29/118 100.0 % 0.71 [ 0.37, 1.38 ]
Subtotal (95% CI) 120 118 100.0 % 0.71 [ 0.43, 1.17 ]
Total events: 21 (Ataluren), 29 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
7 Sinusitis
Kerem 2014 15/120 14/118 100.0 % 1.05 [ 0.43, 2.58 ]
Subtotal (95% CI) 120 118 100.0 % 1.05 [ 0.53, 2.09 ]
Total events: 15 (Ataluren), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
8 Rhinitis
Kerem 2014 12/120 12/118 100.0 % 0.98 [ 0.36, 2.67 ]
Subtotal (95% CI) 120 118 100.0 % 0.98 [ 0.46, 2.10 ]
Total events: 12 (Ataluren), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
9 Upper Respiratory Tract Infection
Kerem 2014 5/120 12/118 100.0 % 0.41 [ 0.11, 1.55 ]
Subtotal (95% CI) 120 118 100.0 % 0.41 [ 0.15, 1.13 ]
Total events: 5 (Ataluren), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
10 Headache
Kerem 2014 20/120 14/118 100.0 % 1.40 [ 0.61, 3.23 ]
Subtotal (95% CI) 120 118 100.0 % 1.40 [ 0.75, 2.65 ]
Total events: 20 (Ataluren), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
11 Acute Kidney Injury
Kerem 2014 18/120 1/118 100.0 % 17.70 [ 1.28, 244.40 ]
Subtotal (95% CI) 120 118 100.0 % 17.70 [ 2.40, 130.47 ]
Total events: 18 (Ataluren), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
12 Pulmonary Exacerbation
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Study or subgroup Ataluren Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,99% CI M-H,Fixed,99% CI
Kerem 2014 92/120 94/118 100.0 % 0.96 [ 0.81, 1.15 ]
Subtotal (95% CI) 120 118 100.0 % 0.96 [ 0.84, 1.10 ]
Total events: 92 (Ataluren), 94 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
13 Cough
Kerem 2014 26/120 35/118 100.0 % 0.73 [ 0.41, 1.30 ]
Subtotal (95% CI) 120 118 100.0 % 0.73 [ 0.47, 1.13 ]
Total events: 26 (Ataluren), 35 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
14 Haemoptysis
Kerem 2014 11/120 18/118 100.0 % 0.60 [ 0.24, 1.52 ]
Subtotal (95% CI) 120 118 100.0 % 0.60 [ 0.30, 1.22 ]
Total events: 11 (Ataluren), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
15 Productive Cough
Kerem 2014 12/120 11/118 100.0 % 1.07 [ 0.39, 2.98 ]
Subtotal (95% CI) 120 118 100.0 % 1.07 [ 0.49, 2.33 ]
Total events: 12 (Ataluren), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
16 Oropharyngeal Pain
Kerem 2014 4/120 14/118 100.0 % 0.28 [ 0.07, 1.16 ]
Subtotal (95% CI) 120 118 100.0 % 0.28 [ 0.10, 0.83 ]
Total events: 4 (Ataluren), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
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Analysis 1.8. Comparison 1 Ataluren versus placebo, Outcome 8 Severity of adverse effects of therapy as
graded by trial authors.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 8 Severity of adverse effects of therapy as graded by trial authors
Study or subgroup Ataluren Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Grade 1 (mild)
Kerem 2014 18/118 20/115 100.0 % 0.88 [ 0.49, 1.57 ]
Subtotal (95% CI) 118 115 100.0 % 0.88 [ 0.49, 1.57 ]
Total events: 18 (Ataluren), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
2 Grade 2 (Moderate)
Kerem 2014 81/118 65/115 100.0 % 1.21 [ 0.99, 1.49 ]
Subtotal (95% CI) 118 115 100.0 % 1.21 [ 0.99, 1.49 ]
Total events: 81 (Ataluren), 65 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
3 Grade 3 (Severe)
Kerem 2014 19/118 30/115 100.0 % 0.62 [ 0.37, 1.03 ]
Subtotal (95% CI) 118 115 100.0 % 0.62 [ 0.37, 1.03 ]
Total events: 19 (Ataluren), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
4 Grade 4 (life-threatening or death)
Kerem 2014 0/118 0/115 Not estimable
Subtotal (95% CI) 118 115 Not estimable
Total events: 0 (Ataluren), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.9. Comparison 1 Ataluren versus placebo, Outcome 9 Pulmonary Exacerbation Rate.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 9 Pulmonary Exacerbation Rate
Study or subgroup Ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Physician Defined Pulmonary Exacerbation Rate
Kerem 2014 116 2.26 (2.36) 116 2.28 (2.69) 100.0 % -0.02 [ -0.67, 0.63 ]
Subtotal (95% CI) 116 116 100.0 % -0.02 [ -0.67, 0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
2 Protocol Defined Pulmonary Exacerbation Rate (as defined by modified Fuchs’ criteria) overall
Kerem 2014 116 1.42 (2) 116 1.78 (2.15) 100.0 % -0.36 [ -0.89, 0.17 ]
Subtotal (95% CI) 116 116 100.0 % -0.36 [ -0.89, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
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Analysis 1.10. Comparison 1 Ataluren versus placebo, Outcome 10 Protocol Defined Pulmonary
Exacerbation Rate: subgroup analysis by chronic inhaled tobramycin use.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 10 Protocol Defined Pulmonary Exacerbation Rate: subgroup analysis by chronic inhaled tobramycin use
Study or subgroup Experimental Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Protocol defined pulmonary exacerbation rate in participants not receiving chronic inhaled tobramycin
Kerem 2014 72 1.42 (2.15) 74 2.18 (2.44) 100.0 % -0.76 [ -1.51, -0.01 ]
Subtotal (95% CI) 72 74 100.0 % -0.76 [ -1.51, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
2 Protocol defined pulmonary exacerbation rate in participants receiving chronic inhaled tobramycin
Kerem 2014 44 1.42 (1.74) 42 1.06 (1.25) 100.0 % 0.36 [ -0.28, 1.00 ]
Subtotal (95% CI) 44 42 100.0 % 0.36 [ -0.28, 1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 5.00, df = 1 (P = 0.03), I2 =80%
-2 -1 0 1 2
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Analysis 1.11. Comparison 1 Ataluren versus placebo, Outcome 11 Total Lung Computerised Tomography
Score - Mean Change From Baseline.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 11 Total Lung Computerised Tomography Score - Mean Change From Baseline
Study or subgroup Ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At up to 48 Weeks
Kerem 2014 99 0.28 (1.34) 104 0.56 (1.56) 100.0 % -0.28 [ -0.68, 0.12 ]
Subtotal (95% CI) 99 104 100.0 % -0.28 [ -0.68, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
-1 -0.5 0 0.5 1
Favours ataluren Favours placebo
Analysis 1.12. Comparison 1 Ataluren versus placebo, Outcome 12 Sweat chloride level - change from
baseline.
Review: Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
Comparison: 1 Ataluren versus placebo
Outcome: 12 Sweat chloride level - change from baseline
Study or subgroup Ataluren Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At up to 48 weeks
Kerem 2014 97 -1.3 (8.94) 97 -0.6 (10.27) 100.0 % -0.70 [ -3.41, 2.01 ]
Subtotal (95% CI) 97 97 100.0 % -0.70 [ -3.41, 2.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
-4 -2 0 2 4
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A D D I T I O N A L T A B L E S
Table 1. Classes of mutations affecting CFTR production, structure, and function
Class Example mutation Impact on CFTR structure and function
I G542X Synthesis of CFTR is critically impaired, and no functional protein is produced. This is due to the
presence of a premature termination codon in the nucleotide sequence. Individuals have no CFTR
function
II phe508del (1F508) A full length of CFTR is produced, but this is structurally abnormal and destroyed by the cell before it
reaches the cell membrane. This is called a defect in the intracellular trafficking pathway. Individuals
have no CFTR function under normal conditions
III G551D CFTR is produced and embedded in the cell membrane, but the chloride channel does not respond
(’switch on’) to normal stimulation from the cell. This means there is no significant ion transport
across the protein. Individuals have no CFTR function
IV R347P CFTR is transported to the outer cell membrane, and responds to normal stimulation, but functions
at a low level because chloride ions do not cross the channel appropriately. Individuals have some
residual CFTR function
V A455E Normal CFTR is produced, but the amount of protein is reduced. Individuals have some residual
CFTR function
CFTR: cystic fibrosis transmembrane conductance regulator
A P P E N D I C E S
Appendix 1. Glossary
Term Explanation
CFTR (cystic fibrosis transmembrane regulator) A protein which is in the outer membrane of cells. It works by regulating transport
of salt in and out of the cell. Problems with the amount of CFTR in the cell
membrane, its structure, or the manner in which it functions can lead to altered
transport of salt across the cell membrane. In the lungs of people with CF, these
problems cause thick airway secretions. Abnormalities of CFTR can also lead to
problems in other organs
CFTR correctors Drugs or chemicals which work by increasing the amount of CFTR in the cell
membrane
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(Continued)
CFTR potentiators Drugs or chemicals which increase the effectiveness of CFTR at transporting salt
across the cell membrane
Nonsense mutation A sequence of DNA that makes no sense resulting in no functional protein being
produced. This is a type of class I mutation (PTC) causing CF
Phenoytype The clinical picture resulting from inherited information.
Premature Termination Codon Also known as a class I mutation; includes nonsense and stop codon mutations
Stop codon mutation A sequence that directs the normal cellular mechanism to stop resulting in no
functional protein being synthesised. This is a type of class I mutation (PTC)
causing CF
Transcription The first step in protein synthesis. Information in a strand of DNA is copied into a
code for the protein which is then used for the construction of a protein molecule.
The process of transcription is faulty in people with CF with class I mutations
C O N T R I B U T I O N S O F A U T H O R S
Roles and responsibilities
TASK WHO UNDERTOOK THE TASK?
Protocol stage: draft the protocol AA with comments from all
Review stage: select which trials to include (2 + 1 arbiter) AA and CH (KS to arbitrate)
Review stage: extract data from trials (2 people) AA and CH
Review stage: enter data into RevMan AA
Review stage: carry out the analysis AA
Review stage: interpret the analysis AA
Review stage: draft the final review AA with comments from all
Update stage: update the review AA, IS and KS
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For the analysis of individual adverse events we have used 99% CIs rather than 95% CIs as the type I error rate (e.g. false positive) is
greatly inflated with a large number of tests.
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